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Abstract
Microarray studies are currently a very popular source of biological information. They allow
the simultaneous measurement of hundreds of thousands of genes, drastically increasing
the amount of data that can be gathered in a small amount of time and also decreasing the
cost of producing such results. Large numbers of high dimensional data sets are currently
being generated and there is an ongoing need to find ways to analyse them to obtain mean-
ingful interpretations. Many microarray experiments are concerned with answering specific
biological or medical questions regarding diseases and treatments. Cancer is one of the most
popular research areas and there is a plethora of data available requiring in depth analysis.
Although the analysis of microarray data has been thoroughly researched over the past ten
years, new approaches still appear regularly, and may lead to a better understanding of the
available information. The size of the modern data sets presents considerable difficulties to
traditional methodologies based on hypothesis testing, and there is a new move towards the
use of machine learning in microarray data analysis.
Two new methods of using prior genetic knowledge in machine learning algorithms have
been developed and their results are compared with existing methods. The prior knowledge
consists of biological pathway data that can be found in on-line databases, and gene ontology
terms. The first method, called “a priori manifold learning” uses the prior knowledge when
constructing a manifold for non-linear feature extraction. It was found to perform better
than both linear principal components analysis (PCA) and the non-linear Isomap algorithm
(without prior knowledge) in both classification accuracy and quality of the clusters. Both
pathway and GO terms were used as prior knowledge, and results showed that using GO
terms can make the models over-fit the data. In the cases where the use of GO terms does
not over-fit, the results are better than PCA, Isomap and a priori manifold learning using
pathways.
The second method, called “the feature selection over pathway segmentation algorithm”,
uses the pathway information to split a big dataset into smaller ones. Then, using AdaBoost,
decision trees are constructed for each of the smaller sets and the sets that achieve higher
classification accuracy are identified. The individual genes in these subsets are assessed
to determine their role in the classification process. Using data sets concerning chronic
myeloid leukaemia (CML) two subsets based on pathways were found to be strongly associ-
viii
ated with the response to treatment. Using a different data set from measurements on lower
grade glioma (LGG) tumours, four informative gene sets were discovered. Further analysis
based on the Gini importance measure identified a set of genes for each cancer type (CML,
LGG) that could predict the response to treatment very accurately (> 90%). Moreover a
single gene that can predict the response to CML treatment accurately was identified.
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Chapter 1
Introduction
1.1 Motivation
New microarray technologies have revolutionised the way genetic experiments have been
conducted by allowing the measurement and analysis of many thousands of genes in par-
allel. Analysing microarray data is a continuous challenge due to the large number of vari-
ables and the noise often associated with the measurements. This high throughput method
generates thousands of variables that must be properly analysed to get some meaningful
results. The relations among the different variables can make the analysis very difficult
[Mur02]. Pairwise relations exist [VP13, RGS08] along with clusters of many related genes
[MCYC06, ESBB98]. For any experiment there is little evidence to suggest in advance how
the genes are related. Despite these difficulties, microarrays have proven useful when it
comes to understanding the genetics of a disease, and have led to the development of new
drugs and therapies. Microarrays have been used to assess many different types of can-
cerous material including leukaemia (acute myeloid leukaemia and acute lymphoblastic
leukaemia) [GST+99] breast cancer [GST+99, SPT+01] and lung cancer [GTS+01, BRS+01].
A lot has been done since the first analytical attempts to cluster microarray data in order to
reveal biologically meaningful patterns [ESBB98]. A number of studies have used statistical
and machine learning techniques. Some studies came up with promising results that can
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be used to improve the treatment of certain diseases. There is however a lot of room for
improvement since due to the number of variables and experimental variance many rela-
tionships and potential information can go unnoticed.
We will focus on cancer data since cancer research is currently a very active field. Many
biological microarray experiments are conducted with the sole purpose of gaining more
information on what causes cancer, how to improve treatment and to discover how people
respond to treatment. There is still a lot to be done due to the multi-factorial nature of
cancer. It depends on genetic, environmental, medical and life style factors which can be
very difficult to capture in one study.
1.1.1 Contribution
This thesis is focused onmethods for reducing the dimensionality of the microarray datasets
in order to make classification easier and less computationally expensive. Principal Com-
ponents Analysis (PCA) and manifold learning (Isomap) are popular methods for linear
and non-linear dimensionality reduction respectively. The novel aspect of the work is in-
vestigating ways in which prior knowledge about gene behaviour can be incorporated in
dimensionality reduction to improve classification. One main source of prior knowledge
that was used was extracted from genetic pathway databases. Several techniques such as
Support Vector Machines, Linear Discriminant Analysis, k - Nearest Neighbours, Decision
Trees and boosting were used in the development of two novel algorithms which are called
“a priori manifold learning ” and “Feature selection over pathway segmentation”. The first
one changes the distance metric between genes to incorporate pathway information when
building a manifold, and the second uses pathway information to split a huge dataset that
previously could not be analysed due to its size, into potentially informative subsets of
genes.
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A prioriManifold Learning Algorithm
For some datasets, especially high-dimensional cancer datasets with a lot of noise, classifiers
often fail in producing accurate results. To overcome this a priori manifold learning was pro-
posed for finding a manifold on which gene relationships can be identified. A representative
set of microarray data is fused with relevant data taken from the KEGG pathway [Kan97] or
the GO term databases [ABB+00, Con15]. Once the manifold has been constructed the raw
microarray data is projected onto it and clustering and classification can take place.
Feature Selection Over Pathway Segmentation
This approach incorporates pathway information found on the ConsensusPath [KSLH13,
KPG+11, KWLH09, POH+10] database with boosting techniques to predict the response of
patients to treatment. Analysing the complete data sets using standard machine learning
methods is currently infeasible due to the huge number of variables and small number of
patients. Adaboost was used with decision trees as weak classifiers on a high-dimensional
dataset of methylation profiles of a set of patients suffering from chronic myeloid leukaemia
(CML) or lower grade glioma (LGG). The genes from two individual pathways were found to
be associated with CML, along with a gene that seems to be predicting the response to treat-
ment with a very high accuracy. In addition gene sets from four pathways were identified
related to LGG. Investigating the decision trees further, it was possible to synthesise two
lists of genes that can perform very well in classifying response in LGG and CML treatment
(> 90% accuracy).
1.1.2 Thesis Scope
The focus of this thesis is on the development of machine learning methods that can iden-
tify patterns of interactions in genes involved in cancer. The main contributions concern
the analysis of microarray data based on the assumption that the data was gathered and
normalised correctly. The datasets used have been suitably processed by the biologists who
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published them. The main results are in demonstrating the viability of the methods pro-
posed, and further work is required to validate them in a clinical context.
Chapter 2
Microarray Data
2.1 From DNA To Gene Expression
Cells are the basic structural, functional and biological units of living organisms. There
are two types of cells: prokaryotic and eukaryotic. Eukaryotic cells are more evolved than
prokaryotic cells. Their main difference is the absence of a nucleus in the prokaryotic cells.
Deoxyribonucleic acid (DNA) is contained in the nucleus, and is formed by two complemen-
tary strands of nucleotides composed of adenine, thymine, cytosine and guanine [Alb08].
The central dogma of genetics is: “DNA makes RNA and RNA makes protein”, a positive
statement which was originally termed “the sequence hypothesis” by Crick, first stated in
1956 [Cri58, CRI70]. DNA contains the code for making proteins, needed by the living
cells. DNA can be copied (DNA replication), it can be transcribed into messenger RNA
(transcription), and proteins can be synthesized using the information in mRNA as a tem-
plate (translation) [Alb08] as shown in figure 2.1. The production of mRNA is often referred
to as gene expression.
DNA replication produces two identical replicas from one original DNA molecule. This
biological process occurs in all living organisms and is the basis for biological inheritance.
Transcription is the process by which the information contained in a section of the DNA is
5
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DNA
mRNA
Protein
Transcription
Replication
Reverse Transcription
Translation
Figure 2.1: DNA Functions
replicated in the form of a newly assembled piece of mRNA. mRNA takes part in protein
generation by transporting the genetic information of DNA out of the cell. There are three
steps to the process of DNA transcription:
1. Initiation: RNA Polymerase (enzyme) binds to DNA. Specific nucleotide sequences tell
RNA polymerase where to begin and where to end (promoter region).
2. Elongation: Proteins, called transcription factors unwind the DNA and allow RNA
polymerase to transcribe only a single strand of DNA into a single stranded RNA poly-
mer called messenger RNA (mRNA).
3. Termination: RNA polymerase moves along the DNA until it reaches a terminator
sequence.
Translation is the process in which cellular ribosomes create proteins. mRNA transcription
from DNA is decoded by a ribosome to produce a specific amino acid chain, or polypeptide.
The polypeptide later folds into an active protein and performs its functions in the cell
[Alb08].
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2.1.1 From DNA To Cancer
Cells have the property to divide and produce new cells either for repairing the old ones or
for letting the body grow. Changes in the DNA attributed to both genetic and epigenetic
factors1 can cause the uncontrolled division of cells. This is called cancer. Cancer cells dis-
place normal cells and use up all of the nutrients in the body to fuel their own uncontrolled
growth, which can cause problems to the correct function of the different organs. The term
cancer is used to describe the abnormal growth of cells that can, for example, form extra tis-
sue called mass and attack other organs [dMFF+12]. s Cancer is among the leading causes of
death worldwide accounting for more than 8 million deaths according to the World Health
Organization. It is expected that the deaths from cancer will rise to 14 million in the next
two decades. Cancer is not a single disease. There are more than 100 known different types
of cancer and probably many more.
Microarray databases are a large source of genetic data, which upon proper analysis, could
enhance our understanding of biology and medicine. Many microarray experiments have
been designed to investigate the genetic mechanisms of cancer. In the last ten years, ma-
chine learning techniques have been investigated in microarray data analysis. Several ap-
proaches have been tried in order to: (i) distinguish between cancerous and non-cancerous
samples; (ii) classify different types of cancer and (iii) to identify subtypes of cancer that may
progress aggressively. All these investigations are seeking to generate biologically meaning-
ful interpretations of complex datasets that are sufficiently interesting to drive follow-up
experimentation.
2.2 DNAMethylation
The exact role of methylation in gene expression is unknown, but it is known that DNA
methylation is essential for cell differentiation and embryonic development [Cai08]. Methy-
1Changes in the regulation of gene activity and expression that are not dependent on gene DNA sequence
but on external factors (i.e. exposures to toxins).
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lation occurs at CpG islands when a methyl group is added to a cytosine residue to convert
it to 5-methylcytosine. A CpG site is a place on the linear sequence of the bases of the
DNA that has a cytosine and guanine separated by only one phosphate. Methylation of
these sites that are in the promoter regions of genes can affect their expression and lead
to their silencing, a feature found in a number of human cancers [JL99]. Methylation can
be used to identify biomarkers for a number of diseases, since it can provide information
about environmental exposures [WH12]. Methylated sites can be detected using bisulfite
conversion, methylation-sensitive restriction enzymes, methyl-binding proteins and anti-
methylcytosine antibodies. These techniques are combined with microarray technology and
high throughput sequencing in order to provide means for genome-wide analysis of the
given samples.
2.3 Measuring Gene Expression Using Microarrays
Microarray technology appeared in mid 90s. A DNA microarray or a DNA chip is a high-
throughput technology for measuring the expression levels of genes. It consists of a small
membrane or glass slide containing many genes arranged in a regular pattern (see figure
2.2). Probes are short strands of DNA, that are used to hybridise the target of interest (usu-
ally complementary DNA - cDNA) as shown in figure 2.3. A high number of complementary
base pairs in a nucleotide sequence means stronger bonding between the two strands.
Figure 2.2:
2Microarray Chips
2Adapted from http://www.nucleomics.be/wp-content/uploads/et_temp/microarrays_AgAndAffy_transparent-
108569_406x226.png
2.3. Measuring Gene Expression Using Microarrays 9
The samples in a microarray experiment are fluorescently labelled, and the measured fluo-
rescence at each spot on the microarray indicates the amount of the corresponding genetic
material in the sample. The fluorescence intensity is captured by scanners into an image
[Lee04].
Figure 2.3:
3How hybridisation takes place on microarrays
Microarray technologies are available for measuring gene expression, DNA copy number,
methylation, chromatin state, protein binding, SNPs, and other aspects of gene physiology
[Rei10] and they have a number of uses including:
1. Gene Discovery: Identification of new genes and their functions.
2. Disease Diagnosis: Characterising different diseases and their genetic differences.
3. DrugDiscovery / Pharmacogenomics: Finding relations between therapeutic responses
to drugs and the genetic profiles of the patients.
4. Toxicological Research: Investigating the impact of toxins on the cells.
Microarrays have several advantages that explain why they are so widely used such as: af-
fordability, no specific equipment is required for their use and, flexibility of design as they
can be manufactured according to the specific experiment [HN09].
3Adapted from http://upload.wikimedia.org/wikipedia/en/thumb/a/a8/NA_hybrid.svg/500px-
NA_hybrid.svg.png
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2.3.1 Gene Expression And Methylation Profiling
During this research two different types of data were used: i) gene expression profiling and
ii) methylation profiling data.
Gene Expression Profiling Using Microarrays
Expression profiling is the process of correlating the genotype (genetic make-up) and the
phenotype (a characteristic of a gene). Not all genes are active and therefore not all genes
are expressed. Changes in the expression of the gene can result in a number of genetic dis-
eases. Gene Expression Profiling provides a comprehensive view of the genes’ activity in the
samples. It quantifies the concentration of a gene’s mRNA transcript in a cell which is the
gene’s expression.
Microarrays immobilise DNA probes on the glass using cDNA, utilising the property of
cDNA sequences to attach to DNA by forming hydrogen bonds4 in a process called hybridi-
sation, which detects the presence of nucleotide sequences that are complementary to the
sequence in the probe. The DNA that was bound to each probe is measured as described
above.
Methylation Profiling Using Microarrays
Three major techniques exist for detecting methylated sites for microarray analysis:
• Methylation-sensitive restriction enzymes: Restriction enzyme-based methods either
enrich for methylated DNA or unmethylated DNA. They are able to detect and cleave
methylation sites for further analysis by looking at the presence of specific enzymes
[LB].
• Bisulfite conversion: Methylated cytosine, one of the four main bases found in DNA
and RNA, has almost the same base-pairing characteristics as unmethylated cytosine,
4Electrostatic attraction between polar molecules
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and is thus indistinguishable by standard sequencing approaches. To overcome this,
genomic DNA can be treated with sodium bisulfite. Under appropriate conditions,
this treatment causes deamination5 of unmethylated cytosine to uracil, while leaving
methylated cytosine intact [PMQC11, SHPF94].
• Affinity purification: Methyl-binding domain (MBD) proteins, such as McrBC, are
used to obtain DNA fractions that are methylated by detecting CpG islands. McrBC is
particularly useful since it recognizes all CpG sites while most methods for methyla-
tion detection are only able to recognise a small fraction of them. Affinity purification
also works with an antibody, instead of a protein, that can recognize methylated cy-
tosines [RMM, WDW+05].
The process of methylation profiling using microarrays measures the methylation levels at
specific locations within the genome using the same process as gene expression profiling.
The probes on the array now represent CpG islands. Every probe is composed of two beads:
one for the methylated cytosine region and another one for the unmethylated. Fluorescent
methylated (using the above methods) and umnethylated DNA is used to hybridise the mi-
croarray. The fluorescence intensity ratios between the two beads are used to calculate the
methylation level.
Differences Between Gene Expression And Methylation Profiling
The difference between the gene expression and the methylation data is shown in table 2.1.
There is a connection between the expression and the methylation data since the presence
of methylation near the transcription site of a gene is associated with reduced expression
[WBG+14] and methylation near the gene promoters varies depending on cell type, with
more methylation of the promoters correlated with low or no transcription [SB08].
5Removal of an amine group from a molecule
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Gene expression Methylation
Gene expression levels are usu-
ally related to the production of
a protein
Methylation levels are related to identify-
ing methylated regions on the DNA which
could be related to silencing a gene and em-
bryonic development
Genetic mechanism Epigenetic mechanism6
Adjacent gene pairs on a chro-
mosome tend to be co-expressed
[KYQG03]
Adjacent probes are often correlated due
to the regional nature of methylation
[PSYK12]
Table 2.1: Gene expression & Methylation profiling differences
2.3.2 Microarrays
The following microarrays are widely are used for both methylation and gene expression
data.
• Bead arrays (Illumina) : gene-specific probes attached to beads and assembled into
arrays.
• Short oligonucleotide7 arrays (Affymetrix): produced by printing short oligonucleotide
sequences designed to represent a single gene or family of gene splice-variants8 by
synthesizing this sequence directly onto the array surface instead of depositing intact
sequences (25-nucleotides long)
• Long oligonucleotide9 arrays (NimbleGen and Agilent): Same as Short oligonucleotide
arrays but with longer probes (60-nucleotides long).
6Changes in the regulation of gene activity and expression that are not dependent on gene DNA sequence
but on external factors (i.e. exposures to toxins).
7Oligonucleotides are short, single-stranded DNA or RNAmolecules that have a wide range of applications
in genetic testing, research, and forensics.
8Gene splicing is a post-transcriptional modification in which a single gene can code for multiple proteins.
9Longer probes are more specific to individual target genes, shorter probes may be spotted in higher density
across the array and are cheaper to manufacture.
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One-Colour Microarrays And Two-Colour Microarrays
1. In one-colour microarrays or single-channel microarrays, each probe or probe set pro-
vides a relative level of hybridisation with the labelled target. They indicate the rela-
tive presence of a gene when compared to other samples or conditions when processed
in the same experiment.
2. Two-colourmicroarrays or two-channelmicroarrays have complementary DNA (cDNA10)
prepared from two samples to be compared (e.g. diseased tissue versus healthy tissue)
and they are labelled with two different fluorophores [SSB96]. The two different types
of DNA samples are mixed and hybridised to a single microarray. Relative intensities
of each fluorophore may then be used in ratio-based analysis to identify up-regulated
and down-regulated genes [TFG+07].
2.4 Microarray Analysis
Microarrays contain between 10,000 and 400,000 different probes. This allows researchers
to assess simultaneously nearly all the genes in the genome. However they generate large
and complicated data sets that are not easy to analyse and validate [Lar05]. The microarray
analysis process works as follows:
1. Experimental Design: An experiment is designed to answer a question. A crucial issue
is whether the number of samples is enough to make the differences in the expression
obvious. Good design principles involve:
• Replication: to reduce uncertainty and variability. Replication should be both
biological and technical. Biological replication means having multiple samples
per group (e.g. healthy, diseased) and technical replication involves RNA from
one sample to be hybridised in multiple arrays.
10Synthesized from a messenger RNA (mRNA) template in a reaction catalysed by the enzyme reverse tran-
scriptase [AJL+02]
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• Blocking: to minimise the effect of existing blocks. This is when samples or pro-
cessing is not homogeneous due to a number of factors (treated under different
conditions, different medication). Local control or blocking is used to reduce the
effects of this. The scientists group experimental units together so that the vari-
ability in the groups is less than among the different units before the grouping.
• Randomisation: to ensure the validity of the results. Randomisation can be over
the individuals assigned to experiments or the order in which the experiments
run.
2. Perform Experiment: DNA is taken from the different samples and is combined with
the microarrays.
3. Quality Assurance: After the experiment the microarrays are checked to determine
the data that is worth analysing. The chips are checked against some ideal reference
values and using deviation plots the technician decides what to keep.
4. Normalisation: Normalisation is the attempt to compensate for systematic techni-
cal differences between chips, to see more clearly the biological differences between
samples [DR04, DHHR02, HvHS+02]. Normalising the microarray data can be done
in three different ways [TOR+01, YS02, YBS01]: Global, Linear and Non-Linear (or
LOWESS). Let logG and logR be the Green and Red background-corrected intensities,
where G and R are the pixel intensities for Green and Red colours respectively. For
constructing the MA plot11: M = log2(R/G) (log-ratios) and A = 1/2log2(RG) (mean
average).
(a) Global normalisation: Normalisation parameters are chosen from the whole of
the array using the global median of log intensity ratios. a0 is the median ofM as
shown in equation 2.1.
(b) (Intensity dependent) Linear normalisation: For two-channel microarrays it is
assumed that the intensities of the two channels have an equal median and there-
fore the normalisation is done by introducing a constant scaling factor making
11Plot for visualising two channel microarrays
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one channel to match the other. (β0,β1) are the least squares estimations for M
and A as shown in equation 2.1.
(c) (Intensity dependent) Non-Linear normalisation (LOWESS): This procedure as-
sumes that the differences are non-linear. It was originally known as locally
weighted polynomial regression, which applies a smooth curve through a set of
data points. LOWESS fits a low-degree polynomial to a subset of the data, using
weighted least squares giving more weight to the points whose response is being
estimated and less to those that are far away.
The normalisation factor for each probe is calculated individually: M∗i (Ai) =Mi − cˆ(Ai)
where cˆ(Ai) is the normalisation coefficient for the probe.
A summary is shown in equation 2.1 [PYK+03].
M =

a0, for global normalisation
β0 + β1A, for linear normalisation
cA, for non-linear normalisation
(2.1)
Measurements can be affected because of a number of things:
• Different amounts of RNA are used for the samples and this can affect the amount
of RNA that is being attached to the probe and consequently its measurement.
• Differences in the dyes: One dye is more readily incorporated than the other (in
2-colour systems) as Red and Green colours have different scanning properties
(detection efficiencies, frequencies); Different amounts of labelling may occur (in
one-colour systems) as there tends to be variation of the dye intensity when the
microarray is being printed depending on the position of the probe on the glass.
• Hybridization conditions may vary (e.g. room temperature, hybridisation time or
even physical differences of the glass of each microarray).
• There may be scanning errors.
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The last two points are called background noise. The scanning laser could be affected
by a surface reflection (this can never be completely eliminated) or by changing the
sensitivity of the scanning device. It could also be affected by debris or salts left over
from hybridisation [Van07]. Noise is handled at the normalisation step. A number
of methods exists to deal with noise: removing potential outliers [KH10], applying
a hierarchical Bayesian ANOVA model [PFS11] and the MAQC-I, MAQC-II, MAQC-
III (SEQC) [MAQ06] projects which provide a collection of tools for quality control,
normalisation and predictive models. It is uncertain how much the noise reduction
helps with the analysis [LK07]. “...the random fluctuations of gene expression signals
caused by technical noise are quite low and the effect of such fluctuations on the results of
statistical inference from Affymetrix GeneChip microarray data is negligibly small” [LK07].
5. Summarisation: Somemicroarrays like Affymetrix andNimbleGen usemany probes to
target one gene (multiple probe oligonucleotide) in order to provide a better measure
of the expression. There are many statistical algorithms that are used to summarise
the gene expression in various probes (MBEI/dChip (Model-Based Expression Intensi-
ties) [LW01], RMA (Robust MultiChip Average) [IBC+03], gcRMA (GeneChip Robust
MultiChip Average) [WI05], FARMS (Factor Analysis for Robust Microarray Summa-
rization) [HCO06] , gMOS [MML03] and BGX [Hei05]) [LEAK11]. In addition there
are simpler methods such as: maxf (takes the probe with the highest fold change12),
minp (takes the probe with the minimum p-value) and wmean (finds the weighted
mean based on the probes p-values).
6. Analysis of the expression results by statisticians.
Despite their vast use microarrays have disadvantages. Identifying correlations in results
does not mean causation. They could as well be accidental or derive from a common cause.
Microarrays do not have the ability to show changes at the protein level. They only allow
profiling at the mRNA level [PTOK00]. Most of the changes on the microarray gene expres-
sion do not correspond to any protein production and they are influenced by other minor
12The ratio of expression values between two conditions
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changes in the experimental conditions [PKMJ07].
2.4.1 Statistical Analysis
The format of the data extracted from the microarray experiment is normally the following:
In =

x1,1 x1,2 · · · · · · x1,n
x2,1 x2,2 · · · · · · x2,n
...
...
... · · · ...
xy,1 xy,2 · · · · · · xy,n︸                           ︷︷                           ︸
X


Y
where X  Y since rows represent patients or samples and columns represent genes. We
invariably have more genes than patients in most of these studies.
Microarray data analysis is used to identify genes that are:
• affected by a treatment
• marker genes that discriminate a diseased from a healthy subject
These genes are used for further experiments and more precise studies regarding a disease
or an experimental treatment.
There are several ways microarrays are used with themost common being having a reference
cell (control) A that is compared to another cell B which has been receiving treatment for a
specific condition. Both cells have the same set of genes in them.
One of the first important experiments using microarrays was done by Spellman [SSZ+98].
He used microarrays for investigating how the gene expression in yeast changes under dif-
ferent stress conditions (heat, carbon, etc.) and during different phases of the cell cycle.
The cell cycle is the process by which the cell divides (more information can be found in
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appendix A). Ideally in the cell cycle there is a balance of dividing and dying cells. Cells
dividing and growing abnormally is a characteristic of cancer [WS12].
Statistical Tests
Statistical tests can be used: for example the z-score, the t-test [Box87] and the Wilcox sign
rank / rank-sum tests, that calculate the difference in the means of two groups and there-
fore give the distance between the two groups in units of standard deviation. Having a
hypothesis H0 (null hypothesis) for two groups T and C:
H0 : µT = µC
where µ is the mean.
Hypothesis testing is often associated with 2 types of error:
Type I: For falsely rejecting the null hypothesis;
Type II: For falsely accepting the null hypothesis
To accept or reject a null hypothesis the p-value is used. The p-value is just the probability
that a data point belongs to the distribution representing a null hypothesis. In our case,
small p-values indicate that it is very unlikely that the observed pattern is random (null
hypothesis). This is because very small p-values are found in the tails of the normal distri-
bution. The decision to accept or reject a null hypothesis is given by the confidence interval.
Confidence intervals can be used for answering the question of statistical significance, re-
gardless of whether a p-values is calculated. A confidence interval is used for the purpose
of estimating a population parameter with a level of confidence. Since sample results vary,
a measure of variability, or margin of error, needs to be added in the results. The sample
statistic, plus or minus a margin of error, gives a range of likely values for the parameter.
This is the confidence interval. The 95% confidence interval consists of all values less than
1.96 standard errors away from the sample value. Similarly, the 99% confidence interval
consists of all values less than 2.58 standard errors away from the sample value.
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Z - Score
The z-score is a measurement of a score’s relationship with the mean. Using the standard
normal distribution it converts a group of data such that the mean is 0 and the standard
deviation is 1. The z-score represents the distance between a sample’s raw score and the
population’s mean in units of the standard deviation. The z-score is shown in equation 2.2,
where µ is the mean and σ is the standard deviation.
z =
x −µ
σ
(2.2)
T - Test
The T - test can be used to establish whether the difference in the mean is significant or not
using the t-test formula in equation 2.3.
t =
X¯T − X¯C√
varT
nT
+ varCnC
(2.3)
where X¯T is the mean of group T and X¯C the mean for group C, varT and varC are the
variances for the different groups and n denotes the number of samples in the group. The
value t can be used to check whether the difference is significant and accept or reject the null
hypothesis H0. The T-test assumes that the groups compared follow a normal distribution
and their standard deviation should be equal.
Wilcox Signed Rank Test
TheWilcox signed rank test [Wil45] is different to the t-test as it does not compare themeans
of the groups. It assesses whether the population mean ranks differ. It is a non-parametric
test that does not assume a normal distribution on the data.
1. Calculate the absolute difference and the sign function sign between each pair of val-
ues:
20 Chapter 2. Microarray Data
for i = 1, ...,N :
|xT i − xCi |
sign(xT i − xCi)
excluding pairs where:
|xT i − xCi | = 0
2. Order the remaining pairs from smallest to largest absolute difference (N )
3. Rank the pairs with the smallest first. If there is a tie the rank received is equal to the
average of the ranks they span across. Rank is denoted by Ri
4. Calculate theW test statistic as shown in equation 2.4.
W =
N∑
i=1
[sign(x2,i − x1,i) ·Ri] (2.4)
5. For a large N: W can be used to calculated the Z-score and accept or reject the null
hypothesis:
z =
W
σW
(2.5)
where σW is:
σW =
√
Nr(Nr +1)(2Nr +1)
6
(2.6)
Regression Analysis
Regression Analysis is often used with hypothesis testing. It fits a function to the data that
describes the relationship between one or more independent variables and a dependent one.
Multiple Linear Regression
The equation for Multiple Linear Regression [Fre05] is shown in equation 2.7. The coeffi-
cients for the model can be estimated using various ways. The simplest is ordinary least
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squares error minimisation. A more advanced way is using gradient descent.
Y = β0 + β1X1 + ...+ βg−1Xg−1 + βgXg + ...+ βp−1Xp−1 (2.7)
Multivariate Logistic Regression
The equation for Multivariate Logistic Regression [Fre05] is shown in equation 2.8. The
coefficients for the model are estimated using maximum-likelihood estimation.
logit(pi(x)) = ln
pi(x)
1−pi(x) =
β0 + β1X1 + ...+ βg−1Xg−1 + βgXg + ...+ βp−1Xp−1
(2.8)
The simplest hypothesis testing using regression is to check whether the slope of a simple
linear regression model (shown in equation 2.9) is 0. If there is a relationship between X
and Y the slope will not be 0. The null hypothesis in this case is that the slope is equal to
zero (shown in equation 2.10).
Y = B0 +B1X (2.9)
H0 : B1 = 0
H1 : B1 , 0
(2.10)
A more complicated case would be to create a reduced model as shown in equation 2.11 and
assume that the rest of the model does not contribute. Therefore H0 : βg = βg+1 = ... = βp−1 =
βp = 0
k = β0 + β1X1 + ...+ βg−1Xg−1 + βg−1 (2.11)
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The F - Statistic is used to compare statistical models and it is therefore used in order to
compare the two hypothesis as shown in equation 2.12.
F =
(SSRFull − SSRReduced)/(p − g)
MSE
(2.12)
where SSR is sum of squares regression (the squared differences between the prediction for
each observation and the population mean) and MSE is the mean squared error.
ANOVA
ANOVA [Fie07], is a set of statistical tools for hypothesis testing or statistical significance
testing of the difference in means and variances of different groups. ANOVA makes four
assumptions:
1. The mean of the response variable is influenced additively and linearly by the factors;
2. The variances of all errors are equal to each other;
3. The errors are independent;
4. The data is normally distributed;
One - Way ANOVA
One - Way ANOVA is used for comparing means between three or more sample groups. Ta-
ble 2.2 shows the different equations for between groups and within groups for calculating
the sum of squares and the mean square error which will later be used for the computation
of the F - test. It is checking how the variation is different between the groups and within
the groups. ni is the sample size of a group i, x¯i is the mean of group i. x¯. is the grand
mean (mean for all groups combined), k is the total number of groups and n is the sample
size. The F - Test is calculated as the ratio of mean square error between groups and mean
square error within groups as shown in equation 2.13. It is a statistical test of the variances
of different groups( H0: the means of the groups are all equal).
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Source Sum Of Squares (SS) Degrees Of Freedom Mean Square Error(MSE)
Between Groups
∑
j nj(x¯j − x¯.)2 k - 1
∑
j nj (x¯j−x¯.)2
k−1
Within Groups
∑
i
∑
j(xij − x¯j )2 n-k
∑
i
∑
j (xij−x¯j )2
n−k
Total
∑
i
∑
j(xij − x¯.)2 n-1 –
Table 2.2: One - Way ANOVA Test
F =
MSBetween
MSWithin
(2.13)
The F value is then used to calculate the p-value.
Two - Way ANOVA
Two - way ANOVA determines how a response is affected by two variables and how they
interact with each other. It is an extension of one - way ANOVA. Assuming a table (T ) with
number of rows (r) and number of columns (c) two - way ANOVA can be calculated using
the information in table 2.3 and table 2.4.
Source Sums
Sum of c observations in ith row TRi =
∑
j xij
Sum of r observations in jth row TCj =
∑
i xij
Sum of rc observations T =
∑
i
∑
j xij
Table 2.3: Two - Way ANOVA Test Observation Sums
Source Sum Of Squares (SS) Degrees Of Freedom Mean Square Error(MS) F-Test
Factor A (rows) SSR =
∑
i
T 2Ri
c − T
2
rc r - 1 MSA =
SSR
r−1
MSA
MSE
Factor B (columns) SSC =
∑
j
T 2Ci
r − T
2
rc c - 1 MSB =
SSC
c−1
MSB
MSE
Interaction SSR,C =
∑
i
∑
j (T
2
ij
n − T
2
rc (r - 1)(c - 1) MSAB
SSR,C
(r−1)(c−1)
MSAB
MSE
Total SST =
∑
i
∑
j(Tij − T 2rc )2 N-1 MST = SSR,C(N−1) –
Sum Of Errors SSE = SST − SSR − SSC − SSR,C N - rc MSE = SSE(N−rc) –
Table 2.4: Two - Way ANOVA Test
One-Way ANOVA is used when the hypothesis considers population means based on one
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characteristic (e.g. one variable is numerical and the other is categorical) while two-way
ANOVA considers population means based on multiple characteristics (e.g. two categorical
variables and a numerical variable). ANOVA is a fast and robust way of analysing data;
however, as described above it makes certain assumptions about the data that need to hold
for the analysis to be correct. Specifically it assumes that the variances of the errors (as well
as the means and variances for each group) are roughly equal which is hardly the case in
real world paradigms. In addition if the null hypothesis is rejected, we only know that at
least one group is different from the others but we do not know which. Multiple testing can
be employed to find out which it is, and it can be computationally expensive when many
groups are considered.
ANOVA is considered to be a more specialised version of regression when the predictors are
categorical. Both of the tests use the sum of squares which makes them similar. There are
however significant differences. A comparison between ANOVA and Regression is shown in
table 2.5.
ANOVA Regression
Performs a test on the variances of different
groups
Fits a function that describes the relation
between different variables
Used for statistical significance testing Can also be used for prediction
Based on one or more categorical predictor
variables
Based on one or more continuous predictor
variables
Parametric - Assumes a distribution over
the data
Does not assume a distribution over the
data
Table 2.5: ANOVA vs Regression
Bootstrapping
Bootstrapping [ET93], involves sampling from a greater population of data in order to ap-
proximate the properties of an estimator. It is particularly useful when the distribution of
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the population is not known. Bootstrap works as shown in algorithm 2.1. Since the distribu-
tion is not known the probability of selecting any element is 1n+m for two populations with
n and m sample sizes. Bootstrapping draws a number of samples from the dataset and per-
forms a statistical test on it. The process is repeatedM times. The number of times the test
statistic has a different value than the statistic given the null hypothesis is used to calculate
the p-value. Bootstrapping has some important limitations when it comes to samples that
are dependent on each other. It fails to capture any such relationships. In addition there
could be occasions where big fluctuations in the data distribution can cause bootstrapping
to fail (adding or removing data can yield very different results).
Algorithm 2.1. Bootstrapping
N = n+m
for i = 1..M do
Draw a bootstrap sample X∗ from N with replacement
θˆ∗ = θˆ(X∗)
end for
p value ≈ #θˆ∗≥θˆ|H0M
2.4.2 Conclusion
Statistically identifying significant genes especially using the t-test can be highly affected
by the variances in the dataset since variance estimates can be altered by genes that have
very low variance. This can cause genes that are not differentially expressed to be identi-
fied as differentially expressed [TTC01]. One of the requirements of most of these tests is
“homogeneity of variance”, which means that the spread of values for each group should
be roughly comparable and the number of samples should also be equal. If this is not the
case and the smallest sample group is associated with the largest variance then it tends to
dominate the t-test. Outliers can also affect the mean and variance of the dataset, making
the chance of rejecting the null hypothesis more difficult. In a dataset where several outliers
exist, the sample variance will increase and therefore the t-test statistic will decrease.
Also most of these techniques assume that the data belongs to a normal distribution, which
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might not always be the case [GK03]. If the dataset is not large enough, normality cannot be
assumed and has to be verified using normality tests. If the number of data points is small,
fluctuations from normality will affect the results of the statistical tests while if there are
many data points, fluctuations will not matter as much. Reasons for non-normality include:
1. Extreme Values: Too many outliers (or extreme values) can cause skewness in the dis-
tribution.
2. Measurement Errors: Faulty equipment or measurement errors canmake the data look
non-normal.
3. Undersampling: the data represents only a subset of the actual dataset.
Techniques that involve sampling may not always reflect the actual population in terms
of diversity and therefore the assumptions drawn might be misleading. Values like the
mean, the variance and the quantiles tend to be different between the samples and the actual
population. This is called sampling error. [MWLN09].
Most statistical methods are univariate, which means that they consider each gene indi-
vidually and do not consider the effect of a gene in relation to the presence or absence of
others. Multivariate methods measure the relative contribution of a gene to the classifica-
tion by considering other genes it might interact with. The methods described above are all
univariate methods. Some of them can be modified to be multivariate (logistic regression,
Multivariate ANOVA). However the problem of choosing a set of features still exists, since
without prior information as to which features are more important, all possible combina-
tions have to be checked which can be computationally expensive and inefficient.
Chapter 3
Mathematical Background
3.1 Dimensionality Reduction
3.1.1 Principal Component Analysis
Principal Components Analysis (PCA) [Pea01] can be used to reduce the dimensionality of
a dataset. It finds the principal variations among the data. Those vectors are orthogonal (i.e.
uncorrelated with each other). The simplification of the data should be done in a way such
that the important features are not lost. The PCA algorithm works as follows:
1. Subtract the mean for each data dimension (to get the mean-adjusted data). Mean is
given by:
X¯ = 1/N
N∑
i=1
X[i] (3.1)
2. Calculate the covariance matrix:
C =
1
n− 1X¯
∗ · X¯ (3.2)
where * is the conjugate transpose operator.
3. Calculate the eigenvectors and eigenvalues of the covariance matrix:
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4. Order the eigenvectors from highest to lowest and choose the ones with the highest
values i.e. the most significant ones. The number of vectors selected will represent the
number of dimensions the new dataset will have.
5. Construct a projection matrix which is a matrix of vectors
featureVector = (eigenV ector1, eigenV ector2, ..., eigenV ectorn) (3.3)
6. Derive the new dataset by transposing and multiplying the feature vector and the
mean adjusted data.
finalDataset = feature VectorT ∗Mean Adjusted DataT (3.4)
This will return the dataset in the axis system defined by the eigenvectors
PCA compares data in terms of similarities and differences.
When computing the principal components (PCs) of a dataset there is no guarantee that
the PCs will be related to the class variable. Therefore, supervised principal component
analysis (SPCA) was proposed [BGAZJ11, CW09a], which selects the PCs based on the class
variables. This extra step was called the gene screening step. SPCA works as follows:
1. Compute the relation measure between each gene with the outcome using linear, lo-
gistic, or proportional hazards models.
2. Select genes most associated with the outcome using cross-validation of the models in
step 1.
3. Estimate the principal component scores using only the selected genes.
4. Fit regression with the outcome using model in step 1
Even though the supervised version of PCA performs better than the unsupervised, PCA
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has an important limitation: it cannot capture non-linear relationships that often exist in
the data, especially in complex biological systems.
Kernel PCA [SSM99] is a non-linear variation of PCA. Kernel PCA uses a mapping K(xi ,xj ) =
φ(xi)Tφ(xj ) called the Kernel Trick. This avoids explicitly calculating the coordinates for
each pair of data in the new space but it just calculates the inner products instead. Popular
kernel functions include:
• Gaussian k(xi,xj) = exp(−γ‖xi − xj‖2) for γ > 0
• Polynomial k(xi,xj) = (xi · xj +1)d
• Hyperbolic Function k(xi,xj) = tanh(κxi · xj + c)
3.1.2 Manifold Learning - Isomap
The manifold learning algorithm is used for non-linear dimensionality reduction [Cay05].
Manifold learning works by taking inputs from a higher dimensional space and embedding
them to a lower one while preserving their topological characteristics. It assumes that all
data points are lying close to or on a manifold and it can be thought as a generalised prin-
cipal components analysis (PCA) that can capture non-linear relations. Isomap [TdSL00],
short for Isometric Mapping, was one of the first approaches to use a manifold and it is an
extension of the Kernel PCA algorithm. An example of the Isomap is shown in figure 3.1
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Figure 3.1: Manifold example with the 3D Swiss roll dataset with N = 1000 data points:
The original dataset is illustrated on the left in the original three-dimensional space. The
Isomap projection to the two-dimensional space on the right was done, by taking a number
of neighbours equal to 8. It can be seen that nearby points in the 2D embedding are also
nearby points in the original 3D manifold, as desired [PVG+11]
.
The Isomap algorithm works as follows:
1. Determine the neighbours: For all points in a fixed radius, find the k nearest points
(k-Isomap) or the closest points based on distance (-Isomap)
2. Construct the neighbourhood graph: Points are connected to each other if they are k
nearest points away with the edge length set to their Euclidean distance.
3. Find the shortest path between all the nodes on the graph using a graph algorithm
(Dijkstra or Floyd-Warshall) to construct the matrix of pairwise geodesic distances
between different points.
4. Construct the lower dimensionality mapping. This is the same procedure as classical
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multi-dimensional scaling (MDS). Generally another matrix Θ is constructed using:
Θ = −1
2
H∆2H (3.5)
where ∆ is the matrix of geodesic distances;
and H is the centring matrix:
H = In − 1NUN (3.6)
where UN is an N ×N matrix of 1’s;
and In is the identity matrix of size n
5. Calculate the eigenvalues ofΘ: Let λk be the kth eigenvalue and vk be the kth eigenvec-
tor. The kth component of the embedding Π is constructed by setting it to
√
λkvk .
Π =

√
λ1v1
√
λ2v2
√
λ3v3
...
√
λdvd

(3.7)
There are several methods for finding manifolds. Locally-Linear Embedding (LLE) [RS00]
is similar to Isomap but uses faster optimization techniques for sparse matrices.
LLE works as follows:
1. For each data point ~Xi , find the neighbours using either the k-nearest neighbours or
by choosing all samples within a fixed distance .
2. Compute the weights that best reconstruct each data point from its neighbours by
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minimising the cost function:
E(W ) =
∑
i
∣∣∣∣~Xi −∑
j,i
Wij ~Xj
∣∣∣∣2 (3.8)
For a point j find the weights that best describe its contribution to the reconstruction
of the point i
3. Each high-dimensional observation ~Xi is mapped to a low-dimensional vector ~Yi rep-
resenting the embedding on the manifold by minimising the cost function:
C(Y ) =
∑
i
∣∣∣∣~Yi −∑
j,i
Wij ~Yj
∣∣∣∣2 (3.9)
In summary there are three steps in the LLE algorithm:
1. Construct the neighbourhood graph for each point in the data by using the k-NN al-
gorithm.
2. Calculate the weights that linearly approximate the data in the neighbourhood.
3. Find the low-dimensional coordinates that best reconstruct these weights and return
the low-dimensional embedding of the original space.
Other forms of manifold include: Hessian Locally-Linear Embedding (Hessian LLE) [DG03]
which is more computationally expensive but uses more sparse matrix techniques for better
results. Modified Locally-Linear Embedding (MLLE) [SPH07], another LLE variant that
uses a localized weighting system. Laplacian Eigenmaps [BN01] uses spectral clustering to
perform dimensionality reduction. Instead of projecting the data, like PCA, and calculating
the distance, manifold learning methods use the intrinsic geometry of the data by assuming
that the data lie on the low-dimensional manifold.
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3.2 Classification
3.2.1 Support Vector Machines
Support Vector Machines are supervised classifiers trained on data. In their simplest form
Support Vector Machines use labelled examples to create a model that will be used to allo-
cate new data in a category using a non-probabilistic binary classifier [CV95] defined by a
separating hyperplane. Given labelled training data, the algorithm outputs an optimal hy-
perplane which classifies new examples. Given a labelled training set xi , yi where i = 1, ...,n
SVMs can find a solution to:
maxw
2
||w|| =minw||w||
2
subject to yi(w
T xi + b) ≥ 1
(3.10)
where b is the bias and w is the weight vector.
Figure 3.2: Support Vector Machines: The kernel function φ maps a lower dimensional
input to a higher dimensional space in order to create the hyperplane for separating the
classes1
The equation that is maximising the distance between the support vectors is selected and
that is why SVMs is considered to be an optimisation problem. The principle of Support
1Adapted from http://i.stack.imgur.com/1gvce.png
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Vector Machines is that they take a low dimensional input and map it, using a kernel func-
tion, to a higher dimensional space in order to be able to create the hyperplane as shown in
figure 3.2. The points lying on the hyperplane are called support vectors. If a kernel is used
the equation 3.10 changes to:
minw = ||w||2
subject to yi(w
Tφ(xi) + b) ≥ 1
(3.11)
for i = 1..N and φ is the kernel function, w is the weights and b is the bias.
3.2.2 Linear Discriminant Analysis
Linear discriminant analysis (LDA) [Fis36] works by finding a linear combination of features
which characterises or separates two or more classes using the Bayes rule:
P(y|X) = P(X |y)P˙(y)/P(X) (3.12)
The boundary between the two classes (k and l) is defined as:
log[P(y = k|X)/P(y = l |X)] (3.13)
which is a log-probability ratio. Linear Discriminant Analysis is similar to Principal Com-
ponents Analysis since they both use linear combinations of variables to describe the data.
Their difference is that LDA takes the class label into consideration while PCA does not.
3.2.3 K - Nearest Neighbours
K-Nearest Neighbours, is a classification algorithm that, based on some distance metric,
most commonly Euclidean distance, selects k samples (neighbours) that lie closest to the
sample to be classified and assigns to it the label of the majority of its neighbours [Die00].
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3.3 Ensemble Methods
To improve the quality of the output, instead of using only one machine learning method, a
combination can be used. These are the ensemble methods.
A classifier is a hypothesis about the true function in respect to the data. Ensem-
ble methods are learning algorithms that construct a set of classifiers and then
classify new data points by taking a vote on their predictions.
Each classifier is an individual hypothesis about the dataset. For ensemble methods to work
as accurately as possible they need to be diverse. Diversity means that they make different
errors in the newly classified data [Die00]. Generally ensemble classification works by:
• Train different classifiers on the training dataset
• Voting done in two ways:
1. Weighted: Different classifiers have different voting power
2. Un-Weighted: All classifiers have the same voting power
Ensemble methods tend to work fairly well since they combine several methods and they
work with majority votes in order to decide on the output. Nevertheless using more than
one classifier can be time consuming especially when the dataset is as large and complex as
microarray data. Common types of ensembles are:
• Boosting: Boosting combines a number of weak classifiers and then takes a majority
vote on their result. It focuses on misclassified samples by training more classifiers on
the instances the previous classifiers failed to label correctly as shown in figure 3.3.
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↗ Classifier1(x) ↘
↓ MisclassifiedSamples
Dataset(x) → Classifieri(x) −→ MajorityVote(Classifier1(x), ...,Classifierk(x))
...MisclassifiedSamples
↘ Classifierk(x) ↗
Figure 3.3: The Boosting Algorithm
• Bootstrap Aggregation (Bagging): A number of classifiers are trained using different
subsets of the dataset and then a majority vote is taken as shown in figure 3.4.
↗ x1→ Classifier1(x1) ↘
...
Dataset(x) → xi→ Classifieri(xi) −→ MajorityVote(Classifier1(x1), ...,Classifierk(xk))
...
↘ xk→ Classifierk(xk) ↗
Figure 3.4: The Bagging Algorithm
• Stacked generalization (Stacking): A number of classifiers are trained using the exist-
ing dataset and then a combiner algorithm is trained on the classifiers to make the
final prediction. The combiner algorithm can be the same as either bagging or boost-
ing; however, it is most frequently just a regression model. The algorithm is shown in
figure 3.5.
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↗ Classifier1(x) ↘
...
Dataset(x) → Classifieri(x) −→ CombinerAlgorithm(Classifier1(x), ...,Classifierk(x))
...
↘ Classifierk(x) ↗
Figure 3.5: The Stacking Algorithm
3.3.1 AdaBoost With Decision Trees As The Weak Classifiers
Adaboost is an ensemble method for classifying that can improve the quality of the output.
AdaBoost starts with one classifier fitted to the dataset and then trains different versions of
it that are again applied on the data. The classifier’s weights are adjusted according to the
accuracy of the result and normally on subsequent runs of the program they are modified
so that they can accommodate the most difficult cases [FS97]. The algorithm used in this
thesis is the AdaBoost-SAMME algorithm [HRZZ09], a multi-class version of the original
algorithm. Decision trees were used as the weak classifiers. They take as inputs tuples
of the form (X,Y ) = (x1,x2, ...,xk ,Y ) and they create rules based on (x1,x2, ...,xk) so that the
target Y can be classified correctly. The tree is constructed by splitting the inputs recursively
(recursive partitioning) and it ends when the subset at a node has items with the same label
or when the accuracy can no longer be improved using the Gini Impurity shown in equation
3.14. The Gini Impurity measures how often a random element can be labelled incorrectly
if a random label was assigned to it based on the distribution of labels on the set.
IG(f ) =
m∑
i=1
fi(1− fi) =
m∑
i=1
(fi − fi2) =
m∑
i=1
fi −
m∑
i=1
fi
2 = 1−
m∑
i=1
fi
2 (3.14)
wherem is the set of values for which the Gini Impurity is calculated and f is the proportion
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of items labelled with the value i in the set. The decision tree algorithm used is the Clas-
sification And Regression Tree (CART) [BFOS84] which works with both categorical and
numerical target variables.
3.4 Internal Cluster Evaluation
3.4.1 Dunn Index
The Dunn Index is an internal evaluation metric for clusters [Dun73]. Internal evaluation
means that it only depends on the data of the cluster itself, mainly by considering the clus-
ters with little variance to be better. It finds the smallest distance between samples in dif-
ferent clusters over the maximum distance of samples in the same cluster, and it is defined
as:
DIm = min
16i6m
 min16j6m,j,i
δ(Ci ,Cj )max
16k6m
∆k

 (3.15)
where δ is the distance metric between the cluster Ci and Cj which can be: single, complete,
average, centroid or Hausdorff [RW98].
and ∆ is
∆i =
∑
x∈Ci
d(x,µ)
|Ci | ,µ =
∑
x∈Ci
x
|Ci | (3.16)
3.4.2 Davies–Bouldin index
The Davies-Bouldin index is another internal evaluation metric [DB79]. It is given by the
equation:
DB ≡ 1
N
N∑
i=1
Di (3.17)
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where Di is the symmetry condition:
Di ≡max
j :i,j
Ri,j (3.18)
and Rij is a measure of how good the clustering scheme is:
Ri,j =
Si + Sj
Mi,j
(3.19)
where S is the measure of scatter inside cluster i andM is the measure of separation between
clusters i and j : Mi,j =
∣∣∣∣∣∣Ai −Aj ∣∣∣∣∣∣ where A denotes the centroids of the clusters i and j . The
Davies - Bouldin index measures the average similarity between each cluster and its most
similar one, averaged over all the clusters. No cluster should be similar to another one and
therefore a good clustering scheme should have a low Davies-Bouldin score.
3.4.3 Silhouette
Silhouette [Rou87] is given by:
si =
bi − ai
maxai , bi
(3.20)
where ai is the average distance of data point i from all other data points within the same
cluster. The closest distance of i from any other cluster is denoted as b(i). Silhouette first
calculates the dissimilarity of the cluster which is the average distance between all cluster
members. Cluster members with low dissimilarity are comfortably within the cluster to
which they have been assigned. The average dissimilarity for a cluster is a measure of how
compact it is. The average distance to fellow cluster members is then compared to the aver-
age distance to members of the neighbouring cluster. The silhouette of a point is defined as
the ratio between its dissimilarity to its own cluster and its dissimilarity to its nearest neigh-
bouring cluster. The silhouette metric can range between -1 and 1. A value of -1 means that
the cluster member is more similar to the members of its neighbouring cluster and a value
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of 1 shows that it is identical to the members of its own cluster.
3.5 Cross-Validation
Cross-Validation [Gei93] is a statistical method for calculating the accuracy of a model by
assessing how well it generalises over an independent data set. It partitions the data in
two groups, the training group and the validation group. The model is created using the
training group and validated over the validation group. To reduce the variance this process
takes place in more than one round using different groups for training and validation and
the results are averaged over the rounds. K-fold-cross-validation using k = 10, is the most
common form [MDA05] since as the k increases the overlap between the training and the test
dataset also increases. A smaller k means that the size of the test set is also smaller which
can lead to less precision. If k is too large the training set size is closer to the full data size
which is not good for training a more generalised algorithm. k = 10 is a good compromise
between a more generalised training and good test sizes. The data is partitioned in ten
groups where nine of them are used as training data and the other one as validation. This
is repeated ten times so that all the groups will be the validation group exactly once. The
results are averaged to produce a single estimation. It is considered to be a good method
because all observations are used for both training and validation. The algorithm is shown
in algorithm 3.1.
3.5.1 Stratified Cross-Validation
In stratified k-fold cross-validation, the training and validation groups are selected so that
the mean response value is approximately equal in all the folds. Since the classification is
binary this means that each fold contains the same number of the two types of class labels
(if the classification is binary).
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Algorithm 3.1. k-Fold Cross Validation
Shuﬄe the training samples (m)
Divide the training samples in k folds (≈m/k)
for i = 1..k do
Train the classifier with the examples that do not belong in fold i
Test the classifier on fold i
Compute ni , the number of examples in fold i that were wrongly classified
end for
Return the classifier error: E =
∑
i=1kni
m
3.5.2 Receiver Operating Characteristic Curves
Receiver operating characteristic curves (ROC curves) are plots that are used for illustrat-
ing the performance of a binary classifier. In a two class classifier there are four possible
outcomes:
1. True Positive: if the outcome from a prediction is p and the actual value is also p;
2. False Positive: if the outcome from a prediction is p however the actual value is n;
3. True Negative: if the outcome from a prediction is n and the actual value is also n;
4. False Negative: if the outcome from a prediction is n however the actual value is p;
The curve is created by plotting the true positive rate against the false positive rate at various
threshold settings. The true-positive rate is also known as sensitivity or recall. The false-
positive rate is also known as the fall-out [Faw06].
Chapter 4
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4.1 Introduction
Machine learning is concerned with programming systems that can learn from the data
provided and improve their performance with experience. Learning involves generalising a
behaviour so that when a new situation comes it can be identified and dealt with. To do that
the system is designed so that it can detect pattens or rules in the data by making a model
and adjusting its performance accordingly. A way to select the most suitable rule model is
by utilising the Occam’s Razor or the Principle of Parsimony [Tho15] which states that:
One should not increase, beyond what is necessary, the number of entities re-
quired to explain anything.
and it goes back to Aristotle, who wrote:
Nature operates in the shortest way possible.
Machine learning can be particularly useful when dealing with large amounts of data and
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complex problems that are not easy for the human brain to solve. It normally proceeds in
two steps:
1. Training: Giving the system enough data to learn from.
2. Classification: Running the learned model on a dataset to classify the data.
Machine learning techniques can be separated into three categories:
• Supervised: which uses only labelled data;
• Unsupervised: which uses unlabelled data;
• Semi–Supervised: which uses labelled and unlabelled data.
In some cases prior knowledge is used to simplify this process. Prior knowledge is all infor-
mation that is available to the system in addition to the training data [lS02]. This informa-
tion is integrated with the training data to get better models of the dataset.
4.2 The Curse Of Dimensionality
In machine learning as the dimensionality of the data rises, the amount of data required to
provide a reliable analysis grows exponentially. Richard E. Bellman referred to this phe-
nomenon as the “curse of dimensionality” when considering problems in dynamic optimi-
sation [Bel57]. A popular approach to the problem of high-dimensional datasets is to search
for a projection of the data onto a smaller number of variables (or features) which preserves
the information as much as possible. Microarray data is typical of this type of small sample
problem. Each data point (sample) can have up to 400,000 variables (gene probes) and pro-
cessing a large number of data points involves high computational cost [KM09]. When the
dimensionality of a dataset grows significantly there is an increasing difficulty in proving
the result statistically significant due to the sparsity of the meaningful data in the dataset
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in question. Large datasets with the so called “large p, small n” problem (where p is the
number of features and n is the number of samples) tend to be prone to over-fitting. An
over-fitted model can mistake small fluctuations for important variance in the data which
can lead to classification errors. This difficulty can also increase due to noisy features. Noise
in a dataset is defined as “the error in the variance of a measured variable” which can result
from errors in measurements or natural variation [Han05]. Machine learning algorithms
tend to be affected by noisy data. Noise should be reduced as much as possible in order
to avoid unnecessary complexity in the inferred models and improve the efficiency of the
algorithm [SLW97]. Common noise can be divided into two types [ZW04]:
1. Attribute Noise
2. Class Noise
Attribute noise is caused by errors in the attribute values (wrongly measured variables,
missing values) while class noise is caused by samples that are labelled to belong in more
than one class and/or misclassifications.
As the dimensionality increases the computational cost also increases, usually exponen-
tially. To overcome this problem it is necessary to find a way to reduce the number of
features under consideration. Two techniques are often used:
1. Feature Subset Selection
2. Feature Extraction
4.3 Feature Subset Selection In Microarray Cancer Data
Feature Subset Selection works by removing features that are not relevant or are redundant.
The subset of features selected should follow the Occam’s Razor principle and also give the
best performance according to some objective function. In many cases this is an NP-hard
4.3. Feature Subset Selection In Microarray Cancer Data 45
(Non-deterministic Polynomial-time hard) problem [Han89, BR92]. The size of the data to
be processed has increased rapidly the past 5 years and therefore feature selection has be-
come a requirement before any kind of classification takes place. Unlike feature extraction
methods, feature selection techniques do not alter the original representation of the data
[SILn07]. One objective for both Feature Subset Selection and Feature Extraction methods
is to avoid over-fitting the data in order to make further analysis possible. The simplest is
feature selection, in which the number of gene probes in an experiment is reduced by select-
ing only the most significant ones according to some criterion such as high levels of activity.
Feature selection algorithms are separated into three categories [Das01, BL97]:
• The Filters: which extract features from the data without any learning involved.
• The Wrappers: that use learning techniques to evaluate which features are useful.
• The Embedded Techniques: which combine the feature selection step and the classifier
construction.
4.3.1 Filters
Filters work without taking the classifier into consideration. This makes them very compu-
tationally efficient. They are divided into multivariate and univariate methods. Multivariate
methods are able to find relationships among the features, while univariate methods con-
sider each feature separately. Gene ranking is a popular statistical method for microarray
data. The following methods were proposed in order to rank the genes in a dataset based on
their significance [XJK01]:
• (Univariate) Unconditional Mixture Modelling: assumes two different states of the
gene on and off and checks whether the underlying binary state of the gene affects the
classification using mixture overlap probability;
• (Univariate) Information Gain Ranking: approximates the conditional distribution
P(C |F) where C is the class label and F is the feature vector. Information gain is used
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as a surrogate for the conditional distribution;
• (Multivariate) Markov Blanket Filtering: finds features that are independent of the
class label so that removing them will not affect the accuracy.
Methods based on correlation have also been suggested:
• (Multivariate) Error-Weighted Uncorrelated Shrunken Centroid (EWUSC): Thismethod
is based on the uncorrelated shrunken centroid (USC) and shrunken centroid (SC). The
shrunken centroid is found by dividing the average gene expression for each gene in
each class by the standard deviation for that gene in that class. This way higher weight
is given to genes whose expression is the same among different samples in the same
class. New samples are assigned to the label with the nearest average pattern (using
squared distance). The uncorrelated shrunken centroid approach removes redundant
features by finding genes that are highly correlated in the set of genes already found
by SC. The EWUSC uses both of these steps and in addition adds error-weights (based
on within-class variability) so that noisy genes will be downgraded and redundant
genes are removed [YB05]. A comparison is shown in figure 4.1 where the three differ-
ent methods are tested on a relatively small (25000 genes, 78 samples) breast cancer
dataset. The algorithms perform well when the number of relevant genes is less than
1000 and generally EWUSC and USC perform better than SC (fewer genes are required
for an accurate model).
Figure 4.1: Comparison between EWUSC, USC and SC on breast cancer data [YB05]
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• (Multivariate) Minimum Redundancy - Maximum Relevance (mRMR): mRMR is a
method that maximises the relevancy of genes within the class label while minimising
the redundancy in each class. To do so it uses several statistical measures. Mutual
Information (MI) measures the information a random variable can give about another,
in particular the gene activity and the class label. This method can be applied to both
categorical and continuous variables. For Categorical (Discrete) Variables, MI is used
to find genes that are not redundant (minimise W ) and are maximally relevant (max-
imise V ) with a target label, as shown in equations 4.1 and 4.2 respectively [DP03],
W =
1
|S |2
∑
i,j∈S
I(i, j) (4.1)
V =
1
|S |
∑
i∈S
I(h, i) (4.2)
where I is the MI, i and j are genes, |S | is the number of features in S and h is a class
label.
Formally, the mutual information of two discrete random variables X and Y can be
defined as:
I(X;Y ) =
∑
y∈Y
∑
x∈X
p(x,y) log
(
p(x,y)
p(x)p(y)
)
, (4.3)
where p(x,y) is the joint probability distribution function of X and Y, and p(x) and p(y)
are the marginal probability distribution functions of X and Y respectively.
For Continuous Variables the F-statistic, that checks whether themeans of two popula-
tions are significantly different, is used to find the maximum relevance between a gene
and a class label and then the correlation of the gene pairs in that class is measured to
minimise redundancy as shown in equations 4.4 and 4.5 respectively [DP03],
V =
1
|S |
∑
i∈S
F(i,h) (4.4)
48 Chapter 4. Dimensionality Reduction For High-Dimensional Microarray Datasets
W =
1
|S |2
∑
i,j∈S
|c(i, j)| (4.5)
where F is the F-statistic, i and j are genes, h is a class label, |S | is the number of
features in S and c is the correlation.
Normalised mutual information can also be used to measure the relevance and redun-
dancy of clusters of genes. The most relevant genes are combined and Leave-One-Out
Cross Validation (LOOCV) is performed to find the accuracy [LKM05]. For continuous
variables linear relationships are used instead of mutual information. MRMRmethods
give lower error accuracies for both categorical and discrete data.
• (Multivariate) Correlation-based feature selection (CFS) as stated by Hall [Hal00] fol-
lows the principle that “a good feature subset is one that contains features highly correlated
with the class, yet uncorrelated with each other”. CFS evaluates a subset by considering
the predictive ability of each one of its features individually and also their degree of
redundancy (or correlation). The difference between CFS and other methods is that it
provides a heuristic merit for a feature subset instead of each feature independently
[WTH+05]. This means that given a function (heuristic), the algorithm can decide
on its next move by selecting the option that maximises the output of this function.
Heuristic functions can also be designed to minimise the cost of reaching the goal.
CFS was used in combination with wrappers (Decision Trees (C4.5), Naive Bayes) and
a number of filters (Relief-F, X2, Information Gain, Information Gain Ratio). Both
filters and wrappers resulted in similar accuracy even though using filters is a much
faster approach.
Relief-F [HS98] is also used with cancer microarray data. It is a multivariate method that
chooses the features that are the most distinguishable among the different classes. It re-
peatedly draws an instance (sample) and based on its neighbours, gives more weight to the
features that help discriminate it from the neighbours of a different class [MBM+04, WM04].
A comparison between Relief-F, Information Gain, Information Gain Ratio and X2 is shown
in figure 4.2. The methods perform similarly across the number of genes selected. Informa-
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tion Gain Ratio is defined as the information gain over the intrinsic information. It performs
normalisation to the information gain using split value information (entropy of the distri-
bution of the instances). The Pearson X2 test evaluates how likely it is that a difference
between the sets has occurred by chance.
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Figure 1. Comparison of the LOOCV accuracy. (a)–(c) Using linear SVM. (d)–(f) Using k-NN.
(LOOCV) accuracy of Relief-F with other feature filtering
methods, including Information Gain, Gain Ratio, and χ2-
statistic, when the top 10, 20, . . . , 150 genes are selected.
When a SVM is applied to a multi-class data set, the one-
versus-the-rest method is used. For the k-NN classifier, we
use the Euclidean distance as the distance metric, and the
best k between 1 and 10 is found by performing LOOCV
on the training data.
Figure 1 shows the results. We can observe from the re-
sults that the performance of Relief-F is slightly better than
other methods on the ALL/AML data set. On the other two
data sets, however, the performance of different feature fil-
tering methods is comparable. Results also show that using
only the top 10 or 20 genes selected by any of the four meth-
ods doesn’t lead to the best LOOCV accuracy.
3.1. Conclusions
This paper empirically compares the performance of the
Relief-F feature filtering method with the other three meth-
ods for selecting informative genes for cancer classifica-
tion using microarray gene expression data. Experimental
results suggest that the performance of Relief-F is compa-
rable with other methods.
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Figure 4.2: Comparison between Relief-F, Information Gain, Information Gain Ratio and
X2 test on ALL and MLL Leukaemia datasets [WM04]
Amethod using independent logistic regressionwith two steps was also proposed [WVOM04].
The first step is an univariate method in which the genes are ranked according to their Pear-
son correlation coefficients. The top genes are considered in the second phase, which is
stepwise variable selection. This is a conditionally univariate method based on the inclu-
sion (or exclusion) of a single gene at a time, conditioned on the variables already included.
Even though all these methods can be highly accurate in classifying information there is
no biological significance proven for the genes that are identified by them. None of the
above methods have indicated whether the results are actually biologically relevant or not.
In addition filter m thods are generally faster than wrapp rs but do not take into account
the classifier which can be a disadvantage. Ignoring the specific heuristics and biases of the
classifier might lower the classification accuracy.
4.3.2 Wrappers
Wrappers tend to perform better in selecting features since they take the model hypothesis
into account by training and testing in the feature space. This leads to the big disadvantage
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of wrappers, the computational inefficiency which is more apparent as the feature space
grows. Unlike filters, they can detect feature dependencies. Wrappers are separated into
two categories: Randomised and Deterministic. A comparison is shown in table 4.1.
Deterministic Randomised
Small Over-fitting Risk High Over-fitting Risk
Prone to Local Optima Less Prone to Local Optima
Classifier Dependent Classifier Dependent
Computationally Intensive Computationally Intensive
Table 4.1: Deterministic vs Randomised Wrappers
Deterministic Wrappers
A number of deterministic wrappers1 have been used to examine breast cancer including
a combination of a wrapper and sequential forward selection (SFS). SFS is a determinis-
tic feature selection method that works by using hill-climbing search to add all possible
single-attribute expansions to the current subset and evaluate them. It starts from an empty
subset of genes and sequentially selects genes, one at a time, until no further improvement
is achieved in the evaluation function. The feature that leads to the best score is added
permanently. The wrappers used were Naive Bayes (NB) and C4.5 in combination with
cross-validation [GFHK09]. For classification, support vector machines (SVM), k-nearest
neighbours and probabilistic neural networks were used in an attempt to classify between
cancerous and non-cancerous breast tumours [OS10]. Very accurate results were achieved
using SVMs. Methods based on SVMs are very popular when analysing microarray cancer
datasets:
1. Gradient-based-leave-one-out gene selection (GLGS) [CVBM02, LSC+09, TSY06, XXL13],
was originally introduced for selecting parameters for the SVMs. It starts by applying
PCA on the dataset. A vector with scaling factors of the new low dimensional space is
1Running them several times will give the same result
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calculated and optimised using a gradient based algorithm and the leave one out error.
Genes are sequentially selected based on a correlation factor.
2. Leave-one-out calculation sequential forward selection (LOOCSFS) is a feature selec-
tion method for cancer data based on Sequential Forward Selection (SFS). It adds fea-
tures in an initially empty set and calculates the leave-one-out cross-validation error
[AM02]. It is an almost unbiased estimator of the generalisation error using SVMs and
C Bound. C Bound is the decision boundary and it is used as a supplementary cri-
terion in the case where different features subsets have the same leave-one-out cross-
validation error (LOOCVE) [LSC+09, GWBV02, LSC+11]. SFS can also add constraints
[GFHK09] on the size of the subset to be selected. It can be used in combination with
the recursive support vector machine (R-SVM) algorithm [JUA05]. Several subsets of
the dataset with different sizes are considered. The R-SVM algorithm calculates the
contribution factor, based on minimal error of the support vector machine, for each
gene and the top ranked genes are chosen for the subset.
LOOCSFS is expected to be an accurate estimator of the generalization error while GLGS
scales very well with high dimensional datasets. The number of the genes in the feature
subset for both LOOCSFS and GLGS has to be given in advance which can be a disadvantage
since the most important genes are not known in advance. GLGS is said to perform better
than LOOCSFS [TSY06, LSC+09].
Randomised Wrappers
Most randomised wrappers2 use Genetic algorithms (GA) (algorithm 4.1) and simulated
annealing (algorithm 4.2).
Linear discriminant analysis was used in combination with genetic algorithms. Subsets of
genes are used as chromosomes and the best 10% of each generation is merged with the pre-
vious ones. Part of the chromosome is the discriminant coefficient which indicates the im-
2Have an element of randomness in them so running them will give a slightly different result every time
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Algorithm 4.1. Genetic Algorithms
Population = Encode(Dataset)
Fitness = f (Population)
while Fitness < Target do
for 1 to Rand() do
Populationi = Population(Rand())
Populationi = Crossover OR Mutation
end for
Fitness = f (Population)
end while
portance of a gene for a class label [HDH08]. Genetic Algorithms - Support Vector Machines
(GA-SVM) [PM12] create a population of chromosomes as binary strings that represent the
subset of features that are evaluated using SVMs.
Simulated annealing is another wrapper technique that works by assuming that some parts
of the current solution belong to a better one, and therefore proceeds to explore the neigh-
bours seeking out solutions that minimise the objective function and therefore avoiding
local optima. Hybrid methods with simulated annealing and genetic algorithms have also
been used [RB12]. A genetic algorithm is run as a first step before the simulated anneal-
ing in order to get the fittest individuals as inputs to the simulated annealing algorithm.
Each solution is evaluated using Fuzzy C-Means3. The problem with genetic algorithms is
that the time complexity becomes O(nlog(n) + nmpg) where n is the number of samples, m
is the dimension of the data sets, p represents the population size and g is the number of
generations. In order for the algorithm to be effective the number of generations and the
population size must be quite large. In addition like all wrappers, randomised algorithms
take up more CPU time and more memory to run.
Best Incremental Ranked Subset (BIRS) [RRAR06], is an algorithm that scores genes based
on their value (using some evaluation measure, in this case Markov Blanket) and class la-
bel and then uses a classifier to identify the most accurate subset of genes from the ones
previously identified. The algorithm is shown in algorithm 4.3.
3A clustering algorithm that uses coefficients to describe how relevant a feature is to a cluster [Dun73,
Bez81].
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Algorithm 4.2. Simulated Annealing Algorithm
Initialise State s = S(0)
Initialise Energy e = E(S(0))
Set time to zero k = 0
while k <kmax And e <emax do
Temperature = temperature(k/kmax)
NewState = neighbour(s)
NewEnergy = E(NewState)
if AcceptanceProbability(e, NewEnergy, Temperature) >random() then
s = NewState
e = NewEnergy
end if
if NewEnergy <EnergyBest then
BestState = NewState
EnergyBest = NewEnergy
end if
k = k + 1
end while
Algorithm 4.3. Best Incremental Ranked Subset (BIRS)
R = ∅
for gene gi ∈ Dataset do
Score = rank(gi , Dataset)
R.add(score)
end for
Sort(R)
BestClass = 0
BestSubset = ∅
for i = 1..N do
TempSubset = BestSubset ∪gi(gi ∈ R)
TempClassifier = WrapperClassifier(BestSubset)
if TempClassifier >BestClass then
BestSubset = TempSubset
BestClass = TempClassifier
end if
end for
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4.3.3 Embedded Techniques
Embedded Techniques tend to perform better computationally than wrappers but they
make classifier-dependent selections that might not work with any other classifier. That
is because the optimal set of genes is built when the classifier is constructed and the selec-
tion is affected by the hypotheses the classifier makes. A well-known embedded technique
is random forests. A random forest is a collection of classifiers. New random forests are cre-
ated iteratively by discarding a small fraction of the genes that have the lowest importance
[DUdA06]. The forest with the smallest amount of features and the lowest error is selected
to be the feature subset. In addition SVMs can be used for both feature selection and classi-
fication. Features that do not contribute to classification are eliminated in each round until
no further improvement in the classification can be achieved [MWB11]. This is called sup-
port vector machines with recursive feature elimination (SVM - RFE). It starts with all the
features and gradually excludes the ones that do not identify separating samples in differ-
ent classes. A feature is considered useful based on its weight resulting from training SVMs
with the current set of features. In order to increase the likelihood that only the “best” fea-
tures are selected, feature elimination progresses gradually and includes cross-validation
steps [ZLS+06, TZH07, LSC+09, TSY05]. A major advantage of SVM-RFE is that it can se-
lect high-quality feature subsets for a particular classifier. It is however computationally
expensive since it goes through all features one by one and it does not take into account
any correlation the features might have [GWBV02]. SVM - RFE was compared against two
wrappers: leave-one-out calculation sequential forward selection and gradient-based-leave-
one-out [TSY06]. All three of these methods have similar computational times when run
against a Hepatocellular Carcinoma dataset (7129 genes, 60 samples). GLGS outperforms
the others, with LOOCSFS and SVM - RFE having similar performance errors [TSY06]. A
comparison of the computational complexity of the algorithms is summarised in figure 4.3.
The most commonly used methods for microarray data analysis are shown in table 4.2.
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Figure 4.3: Computational Complexity Comparison between SVM - RFE, LOOCSFS and
GLGS [TSY06]
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4.4 Feature Extraction In Microarray Cancer Data
Early applications of machine learning to microarray data used simple clustering methods
[ESBB98]. A widely used method was hierarchical clustering. Due to the flexibility of the
clustering methods they became very popular among biologists. Bi-clustering followed hier-
archical clustering as a way of simultaneously clustering both the samples and the features
of a dataset leading to more meaningful clusters. It was shown that bi-clustering performs
better than hierarchical clustering when it comes to microarray data but it is still a compu-
tationally demanding method [PBZ+06]. Many other methods have been implemented for
extracting only the important information from the microarrays thus reducing their size.
Feature Extraction creates new variables as combinations of others to reduce the dimen-
sionality of the selected features. There are two broad categories for feature extraction algo-
rithms: linear and non-linear.
4.4.1 Linear
Linear feature extraction assumes that the data lies on a lower dimensional linear subspace.
It projects it on this subspace using matrix factorization. Given a dataset X: N ×D, there
exists a projectionmatrixU : D×K and a projection Z : N×K , where Z = X ·U . UsingUUT = I
(orthogonal property of eigenvectors), gives X = Z ·UT . A graphical representation is shown
in figure 4.4.
X
D
N = Z
K
N * U
T
D
K
Figure 1: Dimensionality reduction using linear matrix factorization:
Project the data on a lower dimensional linear subspace
1
Figure 4.4: Dimensionality reduction using linear matrix factorization: Projecting the
data onto a lower dimensional linear subspace
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PCA, that was discussed in chapter 3, and many variations of it have been applied as a way
of reducing the dimensionality of cancer microarray data [JS08, LWW02, EBES05, NM09,
MSH+02, RSA00, WG05]. SPCA was also used on microarray datasets [BT04, BPT06]. The
method was highly effective in identifying important genes and in cross validation tests was
only outperformed by gene shaving, a statistical method for clustering similar to hierarchi-
cal clustering. Themain difference is that the genes can be part of more than one cluster. The
term “shaving” comes from the removal or shaving of a percentage of the genes (normally
10%) that have the smallest absolute inner-product with the leading principal component
[HTE+00].
A similar linear approach is classical multidimensional scaling (classical MDS) or Principal
Coordinates Analysis [BG05] which calculates the matrix of dissimilarities for any given
matrix input. It was used for large genomic datasets because it is efficient in combination
with Vector Quantization or K-Means [TLL08] which assigns each observation to a class, out
of a total of K classes [HW79].
4.4.2 Non-Linear
Non-linear dimensionality reduction works in a different way. For example, a low dimen-
sional surface can be mapped onto a high dimensional space so that a non-linear relation-
ship among the features can be found. In theory, a lifting function f (x) can be used to map
the features onto a higher dimensional space. On a higher space the relationship among the
features can be viewed as linear and therefore is easily detected. This is then mapped back
on the lower dimensional space and the relationship can be viewed as non-linear. In prac-
tice kernel functions can be designed to create the same effect without the need to explicitly
compute the lifting function. Another approach to non-linear dimensionality reduction is
by using manifolds. It is based on the assumption that the data (genes of interest) lie on
an embedded non-linear manifold which has lower dimension than the raw data space and
lies within it. Several algorithms exist working in the manifold space and applied to mi-
croarrays. A commonly used method of finding an appropriate manifold, Isomap [TdSL00],
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which was discussed in chapter 3, constructs the manifold by joining each point only to its
nearest neighbours. Distances between points are then taken as geodesic distances on the
resulting graph. Many variants of Isomap have been used, for example Balasubramanian
proposed a tree connected version which differs in the way the neighbourhood graph is con-
structed [BS02]. The k-nearest points are found by constructing a minimum spanning tree
using an -radius hypersphere. This method aims to overcome the drawbacks expressed
by Orsenigo and Vercellis [OV12] regarding the robustness of the Isomap algorithm when
it comes to noise and outliers. These could cause potential problems with the neighbour-
ing graph, especially when the graph is not fully connected. Isomap has been applied on
microarray data with some very good results [DRM05, OV12]. Compared to PCA, Isomap
was able to extract more structural information about the data. In addition, other manifold
algorithms have been used with microarray data such as Locally-Linear Embedding (LLE)
[CL04] and Laplacian Eigenmaps [ERZ+11, KSO02]. PCA and similar manifold methods are
also used for data visualisation as shown in figure 4.5. Clusters can often be better separated
using manifold LLE and Isomap but PCA is a lot faster than the other two.
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averages the worst cases of the clusters’ separations.
One might expect well separated clusters to have smaller
values close to one. In our case, the DB-Index was com-
puted for fixed t rget space dimensions 2,3,5, and 10.
Implementation d tails
The presented benchmark was implemented in Matlab
7.8.0 (R2009a). Furthermore, libsvm (versio 2.89) [43]
served as Support Vector Machine implementation, in
conjunctio with Automatic Model Sel ction for Kernel
Methods (Apr 2005) [44]. The Dimensionality Reduction
Toolbox (versi n 0.7 - Nov 2008) [45], Isomap package
(Release 1 - Dec 2000) [46], LLE routine [45] and MVU
implementati n (version 1.3) [47] were used for dimen-
sion reduction. Because the Isomap and LLE routines
performed best in our benchmark, we converted their
Matlab implementations for the statistical programming
language R [48]. The R-package ‘RDRTo lbox’, also
including a routine to compute the Davis-Bouldin-Index
and our micr array gene exp s ion data simulat , can
be downloaded from [49] (see also Additional file 1).
Results and Discussion
The followi g sections present the results for the Wang
et al. Breast Cancer dataset, which represents best
the results of the whole procedure. For the sake of sim-
plicity, the visualization example in Figure 2 refers to
the Haferlach et al. Leukemia dataset, which consists of
fewer samples. Further detailed analysis of all other
datasets is available in the supplement (see Additional
file 2).
A linear approach like PCA is known to recover the
true structure of data lying on or near a linear subspace
of the high-dimensional input space. The following
results show that the structure of microarray data is
often too complex to be captured well in very low
dimensional target spaces in a linear manner. Nonlinear
methods, in particular LLE and Isomap, preserve more
information in the data than the first few principle com-
ponents of a PCA are able to cover.
Classification
The results of the randomization procedure are shown
in Figure 3. In case of two and three dimensions, PCA
performs worst, while all nonlinear methods, except Dif-
fusion Maps, tend to retain the underlying structure of
the data better in such low-dimensional target spaces.
Table 2 shows the parameters having the best loo-cv
accuracies. The estimated target dimension was higher
than ten in most cases. PCA and Kernel PCA result in
the highest dimensions (14 and 15), while other meth-
ods like Laplacian Eigenmaps, MVU and Isomap worked
best with less than ten dimensions. But classifications in
two or three target dimensions often yield only slightly
different accuracies. The classification accuracies on
data with and without dimension reduction were often
similar, even in two and three target dimensions.
While all methods perform nearly even in higher
dimensions, Isomap, LLE and Laplacian Eigenmaps per-
formed best in two and three dimensions. Only on two
of ten datasets (Alizadeh et. al and Singh et. al), PCA
performed as well as other nonlinear methods like Iso-
map in two or three dimensional target spaces (see Sup-
plemental Figures S18/S19, S27/S28). On all ten datasets
considered together (see supplement), Diffusion Maps
and Laplacian Eigenmaps produce more varying results
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Figure 2 Visualization. Two dimensional visualization example of the Haferlach et al. Leukemia dataset. The LLE and Isomap embedding show
more distinct clusters than the first two principal components of a PCA.
Bartenhagen et al. BMC Bioinformatics 2010, 11:567
http://www.biomedcentral.com/1471-2105/11/567
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Figure 4.5: Visualisation of a Leukaemia dataset with PCA, manifold LLE and manifold
Isomap [BKR+10]
Another non-linear method for classification is Kernel PCA. It has been regularly used
[RVO14, LCB05] since dimensionality reduction helps with the interpretability of the re-
sults. It does have an important limitation in terms of space complexity since it stores all
the dot products of the training set and therefore the size of the matrix increases quadrati-
cally with the number of data points [LY09].
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Neural methods, like Self Organizing Maps (SOMs) are also used for dimensionality reduc-
tion [Koh88]. SOMs or Kohonen maps create a lower dimensional mapping of an input by
preserving its topological characteristics. They are composed of nodes or neurons and each
node is associated with its own weight vector. SOMs training is considered to be “compet-
itive” since when a training example is fed to the network its Euclidean distance with all
nodes is calculated and it is assigned to the node with the smallest distance (Best Match-
ing Unit (BMU)). The weight of that node along with its neighbouring nodes is adjusted to
match the input. SOMs have been used as a method of dimensionality reduction for gene
expression data [KNT+01, KSO02] but they were never broadly adopted for analysis because
they need just the right amount of data to perform well. Insufficient or extraneous data can
cause randomness to the clusters. Another neural network method for dimensionality re-
duction (and dimensionality expansion) uses autoencoders. Autoencoders are feed-forward
neural networks which are trained to approximate a function by which data can be classi-
fied. For every training input the difference between the input and the output is measured
(using square error) and it is back-propagated through the neural network to perform the
weight updates to the different layers. In a paper that compares stacked autoencoders with
PCA with Gaussian SVM on 13 gene expression datasets, it was shown that autoencoders
perform better on the majority of datasets [RFAM13]. Autoencoders use fine tuning, a back-
propagation method for adjusting their parameters. Without back-propagation the autoen-
coders suffer from very low accuracies. A general problem with autoencoders is that a large
number of internal layers can easily “memorise” the training data and create a model with
zero error which will over-fit the data and be unable to classify future test data.
Independent Component Analysis (ICA) is also used for analysing microarray data [LB03,
EDMA10] in combination with a clustering method. ICA finds the correlation among the
data, and decorrelates it by maximizing or minimizing the contrast information. This is
called “whitening”. The whitened matrix is then rotated to minimise the Gaussianity of
the projection and in effect retrieves statistically independent data. It can be applied in
combination with PCA. It is said that ICA works better if the data has been preprocessed
with PCA [CCC+03]. This could, however, merely be due to the decrease in computational
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load caused by the reduced dimensionality.
2666664
X1
X2
...
XN 1
XN
3777775 !
26664
Xi
...
Xk
Xn
37775
2666664
X1
X2
...
XN 1
XN
3777775!
264Y1...
YK
375 = f
0BBBBB@
2666664
X1
X2
...
XN 1
XN
3777775
1CCCCCA
Figure 1: Feature Selection And Feature Extraction: Di↵erence between
feature selection (top) and feature extraction (bottom)
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Figure 4.6: Feature Selection And Feature Extraction: Difference between feature selection
(top) and feature extraction (bottom)
The advantages and disadvantages of feature extraction and feature selection are shown in
table 4.3 and their differences in figure 4.6.
Method Advantages Disadvantages
Selection
Preserves data characteristics for interpretability
Lower training times
Reduced over-fitting
Discriminative power
Extraction
Higher discriminating power
Control of over-fitting when unsupervised
Loss of Data interpretability
Transformation maybe expensive
Table 4.3: Advantages and Disadvantages between Feature Selection And Feature Extrac-
tion Approaches
4.4.3 Affinity Matrices
Many classification algorithms use feature extraction from an affinity matrix, which records
the similarity in the behaviour of each pair of variables in the problem. In the case of
cancer data analysis we intuitively think of the genes as being variables whose values is
an activity level measured by one or more spots on a microarray, and the classes of interest
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are cancer subtypes, or more simply the sets of subtypes that will go into remission and
those that will not. In this interpretation the affinity matrix will have the dimension of the
number of genes, or gene probes, and consequently will be very large. We refer to this as
the gene-by-gene affinity matrix. The similarity value that we calculate for each gene pair
is based on extracting a tuple from each patient case (or sample). The number of these data
points is comparatively small. Similarity may be computed by any distance metric, but the
most commonly used is linear correlation. An alternative way to address the problem is
to consider that each patient case (sample) is a variable. In this case the dimension of the
affinity matrix is the same as the number of samples, and consequently is usually small. It
is referred to as the sample-by-sample affinity matrix. If PCA is used for feature extraction
then there is a direct relationship, known as the Kohonen-Lowe transformation, between
the features extracted from the two forms of the affinity matrix.
Let us suppose the data is arranged in a matrix U where the columns are the gene probe
measurements and the rows are the samples (or patient cases). Let there be n columns and
N rows. The data can be mean-centred by subtracting the average of each column from each
of its entries. Using correlation as the similarity measure we have that:
Σg =U ×UT /(N − 1)
Σs =UT ×U/(N − 1)
where Σg is the gene-gene affinity matrix, Σs is the sample-sample affinity matrix and N is
the number of samples. The features used in classification are the eigenvectors of the affinity
matrix, so starting with the sample-sample affinity matrix we compute the set of features Φs
using:
ΣsΦs =ΦsΛ
(UUT )Φs =ΦsΛ
If we multiply both sides by UT we get:
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UT (UUT )Φs =UTΦsΛ
(UTU )(UTΦs) = (UTΦs)Λ
the features Φg extracted from the gene-gene affinity matrix are given by:
ΣgΦg =ΦgΛ
(UTU )Φg =ΦgΛ
from which we can infer that:
Φg =UTΦs
Although the number of eigenvectors extracted from the gene-genematrix (n) is much larger
than the number extracted from the sample-sample matrix (N ), in both cases the number of
eigenvectors with non-zero eigenvalues will be N-1 because, assuming the samples are all
linearly independent, the rank of both affinity matrices is N −1. Computationally it is much
faster to calculate UTΦs than to calculate Φg directly, since eigenvector extraction scales
with the square of the dimension of the data, and no information is lost in the process.
4.5 Prior Knowledge
Prior knowledge has previously been used in microarray studies with the objective of im-
proving the classification accuracy. One early method for adding prior knowledge in a ma-
chine learning algorithm was introduced by Eran Segal [SKFJ05]. It first partitions the vari-
ables into modules, which are gene sets that have the same statistical behaviour (share the
same parents in a probabilistic network) and then uses this information to learn patterns.
The modules were constructed using Bayesian networks and a Bayesian Scoring function to
decide how well a variable fits in a module. The parents for each module were restricted
to only some hundreds of possible genes otherwise the model was becoming too complex.
Regression Trees were used to learn the module networks. The gene expression data was
64 Chapter 4. Dimensionality Reduction For High-Dimensional Microarray Datasets
taken from yeast in order to investigate how it responds to different stress conditions. The
results were then verified using the Saccharomyces Genome Database [CHA+12]. Adding
prior knowledge reduces the complexity of themodel and the number of parameters making
analysis easier. A disadvantage however of this method is that it relies only on gene expres-
sion data, which is noisy. Many sources of external biological information are available and
can be integrated with machine learning and/or dimensionality reduction methods. This
helps overcome one of the limitations of machine learning classification methods which is
that they do not provide the necessary biological connection with the output. Adding exter-
nal information with microarray data can give an insight to the functional annotation of the
genes and the role they play in a disease, such as cancer.
4.5.1 Gene Ontology
Gene Ontology (GO) terms are a popular source of prior knowledge since they describe
known functions of genes. Protein information found in the genes’ GO indices has been
combined with their expressions in order to identify more meaningful relationships among
the genes [CX04, HP06]. A study infused GO information in a dissimilarity matrix [KZ10]
using Lin’s similarity measure [Lin98] in order to make the clustering results more biologi-
cally relevant. GO terms were also used as a way of weighting the longest partial path shared
by two genes [CCM+04]. A pair-wise similarity matrix of gene expressions and the weight
derived from the GO data were added together in order to produce gene clusters. Clusters
created using GO terms were denser and more biologically relevant (genes detected were
related to the particular type of cancer) than without the GO terms. GO term information
integrated with gene expression was used by Chen and Wang [CW09b]. They applied SPCA
to find the most significant principal components and classify cancer survival .
Not all of these methods have been compared to other forms of dimensionality reduction
such as PCA or manifold which is a serious shortcoming as to their actual performance. It
is however the case that in all of those papers some important limitations of GO terms are
described. Some genes do not belong in a functional group and therefore cannot be used.
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GO terms tend to be very general when it comes to the functional categories and that leads
to bigger gene clusters that are not necessarily relevant in microarray experiments.
4.5.2 Protein-Protein Interaction
Other studies have used protein-protein interaction (PPI) networks for the same purpose
[CLL+07]. Subnetworks are identified using PPI information. Iteratively more interactions
are added to each subnetwork and scored using mutual information between the expression
information and the class label in order to find the most significant subnetwork. The initial
study showed that there is potential for using PPI networks but there is a lot of work to be
done in order to take advantage of the prior knowledge more effectively. Prior knowledge
methods tend to use this knowledge in order to filter data out or even penalise features.
These features are called outliers and normally are the ones that have a much higher vari-
ance than every other point. Su et al. [SYD10] overlaid PPI and gene expression data. Using
the PPI information genes that belonged in the same PPI network were tested for correlation
and high discriminatory power. The top scoring PPI networks were combined in a single
network. The genes belonging to the final network were removed from the PPI dataset and
the process was repeated. The results showed that this method could classify breast cancer
metastasis accurately using the genes in the final network.
4.5.3 Gene Pathways
The most promising results have been shown when using pathway information as prior
knowledge. Many databases containing information on networks of molecular interaction
in different organisms exists (KEGG, Pathway Interaction Database, Reactome, etc). It is
widely believed that these lower level interactions can be seen as the building blocks of
genetic systems, and can be used to understand high-level functions of the biological sys-
tems. KEGG pathways have been quite popular in network constrained methods which use
networks to identify gene relations to diseases. A network-based penalty function for vari-
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able selection has been introduced [LL08]. The framework used penalised regression, after
imposing a smoothness assumption on the regression coefficients based on their location
in the gene network. The biological motivation for this penalty is that the genes that are
linked on the networks are expected to have similar functions and therefore bigger coeffi-
cients. The weights are also penalised using the sum of squares of the scaled difference of
the coefficients between neighbour vertices in the network in order to smooth the regression
coefficients. The results were promising in terms of identifying networks and subnetworks
of genes that are responsible for a disease. However the authors only used 33 networks and
not the entire set of available networks. A similar theoretical approach also exists, which
according to the authors can be applied to cancer microarray data but to date has not been
explored [RZD+07]. The proposed method was based on Fourier transformation and spec-
tral graph analysis. The gene expression profiles were reconstructed using prior knowledge
from gene networks to modify the distance. They use the assumption that the informa-
tion lies in the low frequency component of the gene expression while the high frequency
component is mostly noise. Using spectral decomposition the smaller eigenvalues and cor-
responding eigenvectors are kept (the smaller the eigenvalue the smoother the graph). A
linear classifier can be inferred by penalising the regression coefficients based on network
information. The Biological Pathway-Based Feature Selection Algorithm (BPFS) [BKG+09]
also utilizes pathway information for microarray classification. It uses SVMs to calculate the
marginal classification power of the genes and puts those genes in a separate set. Then the
Influence Factor for each of the genes in the second set is calculated. This is an indication
of the interaction of every gene in the second set with the already selected genes. If the
Influence factor is low the genes are added to the set of the selected genes. The Influence
factor is the sum of the shortest pathway distance that connects the gene to be added with
each other gene in the set.
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4.6 Discussion
Feature selection methods that perform statistical analysis tend to be less computationally
expensive than feature extraction methods. Most feature selection methods work using sta-
tistical significance tests. However these methods have trouble dealing with datasets where
the number of samples is much smaller than the number of features. Due to improvements
in sequencing techniques, microarray experiments can now capture information for all the
genes in the human genome, which leads to datasets of hundreds of thousands of features.
In addition most of these methods require the variances of the different classes to be iden-
tical. This is not always the case when dealing with biological data that can be extremely
noisy and contain outliers. In addition, the normality assumption does not always hold,
especially when the number of samples is small, which is a pre-requisite for proving signif-
icance for statistical analysis tests. Another problem is that even for multivariate methods,
it is difficult to check all the possible combinations of genes. Unless prior information is
used it is computationally expensive and therefore it is limited to some groups of genes that
either have specific expression patterns or are identified using combinatorial searches in the
dataset. Methods like SVM-RFE or random forests tend to be restricted to only one classifier
and are not widely applicable to others.
Feature extraction methods face similar problems, due to the high dimensionality of the
microarray datasets. Moreover there is no connection between the output and its biological
meaning. Some of the genes that are identified by the model as important might not be
related to the actual outcome and are just part of the model because they exhibit specific
expression patterns, which could be due to the noisy nature of the microarray data. Some
biological component needs to be added in order to make classification more accurate and
more specific to the problem.
Adding prior biological knowledge in machine learning algorithms is gaining more popu-
larity, since it is a way of dealing with the growing size of the datasets. Care must be taken
when the prior knowledge is integrated in the model so it will not over-fit. Adding prior
knowledge without integrating it with the dataset information, or using it as a way of pre-
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processing it to filter out information, will result in models that reflect the prior knowledge
instead of a combination between the prior knowledge and the microarray dataset. The
prior knowledge used needs to come from a reliable, well curated source. Pathways are
the most popular source now but most of the methods proposed only use a fraction of the
available pathways.
Chapter 5
A prioriManifold Learning
5.1 Introduction
In this chapter a method which incorporates manifold learning along with a novel approach
for estimating the k-Nearest Neighbours is presented.
A new way of constructing the manifold was investigated which makes use of prior knowl-
edge. Prior knowledge has previously been used inmicroarray studies [CX04, KZ10, CCM+04]
with the objective of improving the classification accuracy. Although several types of prior
knowledge could have been used, the KEGG pathways database was deemed to be best for
this purpose, since the KEGG pathway database describe actual interactions between genes.
KEGG (Kyoto Encyclopedia of Genes and Genomes) [Kan97] is a collection of databases
containing information on networks of molecular interactions in different organisms. It
is believed that these lower level interactions can be seen as the building blocks of ge-
netic systems, and can be used to understand high-level functions of biological systems.
KEGG pathways have been a popular in network constrained methods which use networks
to identify gene relations to diseases [LL08, RZD+07]. Other studies have used protein-
to-protein interaction (PPI) networks for the same purpose [CLL+07]. Gene Ontology (GO)
terms are a popular source of prior knowledge since they describe known functions of genes
[CW09b, CX04, KZ10, CCM+04].
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The proposed method of building the manifold is as follows. In common with all previous
methods the affinity matrix is built first from a set of microarrays. A gene-by-gene affinity
matrix is a square matrix whose dimension is the same as the number of gene probes in
the microarray data. The matrix is symmetric and each entry is a similarity measure (for
example covariance) of the expression levels of the two genes that index it. The information
from the KEGG pathways was then fused with the affinity matrix by increasing the values
for gene pairs with a strong relationship in KEGG. Next a conventional manifold learning
method was applied to the fused affinity matrix to find the manifold. Having found the
manifold of the gene probes the raw data is projected onto it so that the classification ex-
periments can be carried out. This means that the KEGG pathway data is only involved in
building the manifold. In contrast to previous data fusion approaches [TP07] , the prior
knowledge is only used to find a suitable space for representing the data. This ensures that
the results are more specific to the biological content of the dataset under investigation. In
contrast to other prior knowledge methods, a priori manifold learning does not use prior
knowledge to filter out data from the original dataset, or just weight the affinity matrix.
The cluster validation and accuracy measurements, along with the original Isomap algo-
rithm and PCA were built using the sklearn [PVG+11] package for Python. The method was
developed by myself and MEng student George Trigeorgis. The original paper can be found
in [HTG14].
5.2 The A PrioriManifold Learning Algorithm
Biological pathways are usually directed graphs with labelled nodes and edges representing
associations of genes participating in a biological process. These interactions can help in
understanding the underlying processes in different organisms as well as their contribution
to diseases. Some of the interactions include regulation of gene expression, transmission
of signals and metabolic processes. It is not yet completely clear as to why and how these
interactions came to exist andwhat other, if any, external factors contribute to them. When it
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comes to machine learning, information from the pathways can be used as prior knowledge
for either feature selection or dimensionality reduction of the original data set. For this
implementation, KEGG pathways are used as a way to weight the distance between the gene-
to-gene interactions. Genes that share a greater number of common pathways should have
a higher probability in being closer together when it comes to clustering, since it is already
known that they interact with each other. The metric used in weighting the distances was
based on a feature selection method [CSTK01]. This method works by assigning weights on
the different features so that the more important ones play a greater role in the equation.
By exploiting the use of these weights the classical k-nearest points algorithm using the
weighted Mahalanobis distance was modified as shown in equation (5.4).
The algorithm to find the k-nearest points works as follows:
1. Given a pair of probes the Jaccard coefficient is used to evaluate the similarity of path-
ways they share together. This index, coined by Paul Jaccard [Jac01] and shown in
equation 5.1, is a statistic commonly used for comparing similarity and diversity of
sample sets.
R(i, j) =
|ξ(i)∩ ξ(j)|
|ξ(i)∪ ξ(j)| (5.1)
where ξ ⊂ power-set of the KEGG Pathway.
2. The distance metric selected to calculate the gene-to-gene distance is the Mahalanobis
distance. It is measured using the correlations between two gene feature sets.
d(~x,~y) =
√
(~x − ~y)TS−1(~x − ~y) (5.2)
where S is the covariance matrix.
3. The weights equation is shown in equation for genes i and j is shown in equation 5.3
wij = exp(−η ×R(i, j)) (5.3)
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where η is a learning parameter and R is the Jaccard coefficient. The learning param-
eter η is a way of minimising or maximising the influence of any given feature in the
dataset. When η is large the changes in the dataset are exponentially reflected on the
weights. For example the way the parameter η affects endometrial cancer results is
shown in figure 5.1. The η value selected for the embedding of the endometrial cancer
was 19000. It is the value with the highest Dunn index as shown in the figure 5.1
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Figure 5.1: Endometrium Cancer: How the η value affects the value for the Dunn index
The η value was optimised using grid search [BB12]. Grid search works with cross-
validation and is a simple, general purpose method that can always be applied. It
involves computing the error at every point on a grid spanning the range of parameter
values. In our case there was a predefined range of η values the algorithm had to run
for, for example, from 0 to 10000 with a step of 100. Because that range was large
and would take a lot of CPU time, a variation of the randomised grid search was used.
Initially the algorithm run for all values as long as the accuracy was increasing. The
algorithm was run using randomly sampled grid points (without replacement). The
grid point with the largest η value was recorded. After sampling a specific number of
points without improvement of the accuracy the algorithm was terminating.
4. The weights along with the Mahalanobis distance are expressed as:
D(i, j) =
√
wi,j × d(~i,~j) (5.4)
where i and j are two different probes.
5.3. Datasets 73
This is shown in algorithm 5.1.
Algorithm 5.1. Calculation of the k-Nearest points of the manifold: First the Jaccard
coefficient is calculated, then the Mahalanobis distances among the genes and the weights.
for each probe i in probes do
for each probe j in probes do
R(i, j) =
|ξ(i)∩ ξ(j)|
|ξ(i)∪ ξ(j)|
end for
end for
R = R∑
i,j R(i,j)
for each probe i in probes do
for each probe j in probes do
wij = exp(−η ×R(i, j))
distance(i, j) =
√
wij ×∑nk=1Mahalanobis(ik , jk)
end for
NearestNeighbours(i) = sorted(distances(i))
end for
The shortest paths ∆ are found using either the Dijkstra [Dij59] or Floyd-Warshall algorithm
[Flo62]. Dijkstra’s algorithm is usually preferred since it is faster and the weights are non-
negative. The Isomap mapping is performed by calculating the eigenvalues of Θ as shown
in equation 3.5.
5.3 Datasets
To verify the effectiveness of a priori manifold learning algorithm the following datasets
were used:
1. GEMLeR [SK10], which provides a collection of gene expression datasets that can be
used for benchmarking gene expression oriented machine learning algorithms. Each
of the gene expression samples in GEMLeR came from a large publicly available repos-
itory. GEMLeR was mainly preferred because:
• The processing procedure of tissue samples is consistent;
• The same Affymetrix microarray assay platform is used (Affymetrix GeneChip
U133 Plus 2.0);
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• There is a large number of samples for different tumour types;
• Additional information is available for combined genotype-phenotype studies.
2. Acute lymphoblastic leukaemia (ALL) dataset. ALL is a form of leukaemia charac-
terised by excess lymphoblasts. There are two main types of acute leukaemia: T-cell
ALL and B-cell ALL. T-Cell acute leukaemia is aggressive, progresses quickly and is
more common in older children and teenagers. B-Cell ALL leukaemia [CSG09] is an-
other type of ALL, originating in a single cell and characterised by the accumulation
of blast cells that are phenomenologically reminiscent of normal stages of B-cell dif-
ferentiation.
A summary of the datasets is shown in table 5.1. For the experiments in Chapter 5 and
Chapter 6 the classification method was "one-vs-all". There was a total of 1545 samples in
the dataset for 9 types of cancer (Breast, Colon, Kidney, Ovary, Lung, Uterus, Omentum,
Prostate, Endometrium). The experiments done, were for distinguishing between the differ-
ent types of. For example for breast cancer, the breast cancer samples were left intact and
everything else was marked as "other". Therefore the classification was binary. The a pri-
ori manifold learning algorithm was used to devise a model that can separate breast cancer
from every other cancer in the dataset. The Acute Lymphoblastic Leukaemia dataset was
not used for classification but only for visualisation purposes for the three different types of
leukaemia.
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Type Of Cancer Number Of Samples Number Of Genes
Breast Cancer 344 cancer samples vs Other (1201 samples) 10935
Colon Cancer 286 cancer samples vs Other (1259 samples) 10935
Kidney Cancer 260 cancer samples vs Other (1285 samples) 10935
Ovary Cancer 198 cancer samples vs Other (1347 samples) 10935
Lung Cancer 126 cancer samples vs Other (1419 samples) 10935
Uterus Cancer 124 cancer samples vs Other (1421 samples) 10935
Omentum Cancer 77 cancer samples vs Other (1468 samples) 10935
Prostate Cancer 69 cancer samples vs Other (1476 samples) 10935
Endometrium Cancer 61 cancer samples vs Other (1484 samples) 10935
Acute Lymphoblastic Leukaemia 19 B-Cell vs 8 T-Cell vs 11 Normal 5000
Table 5.1: Datasets Used
5.4 Results
A priori manifold learning was tested against the original Isomap algorithm and PCA. The
Dunn index was used as a metric for evaluating the density and the structure of the clusters
in the embedding. The k-Nearest Neighbours (k-NN), Support Vector Machines (SVMs) and
Linear Discriminant Analysis (LDA) classifiers were applied along with 10-fold cross vali-
dation to test the accuracy of the model. Nine different types of cancer were used to evaluate
the methods (GEMLeR) and a smaller dataset (ALL) was used to visualise the results. The
datasets are described in table 5.1. The evaluation scheme is shown in figure 5.2.
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Figure 5.2: Evaluation benchmark: The η parameter is estimated and the resulting embed-
ding is evaluated using cluster quality and cross validation metrics
5.4.1 Internal Evaluation
Dunn Index
The Dunn index was discussed in chapter 3. For these experiments the Dunn index can
indicate how well the resulting embedding separates the samples according to their label,
since it uses the labels of each sample as the cluster indicators. In practice manifold learning
does not create any clusters but if the embedding is done in a successful way many points
will end up being next to each other, since the embedding is just a mapping from the original
dataset to a different space. This experiment was run for different dimensional embeddings
(2 to 50 components) as the component that will end up being used in the embedding is
heavily dependent on the complexity of the data.
A priori manifold learning is implemented using a gene-by-gene affinity matrix, since the
prior knowledge involved is in the form of gene to gene similarities, and is applied to the
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affinity matrix rather than to the original data. It is not possible to construct a correspond-
ing sample-by-sample affinity matrix for this algorithm. However classification using the
standard PCA and ISOMAP algorithms, which do not involve prior knowledge, can be com-
puted using features drawn from either form of the affinity matrix. Figures 5.3 and 5.4
compare the a priori manifold learning algorithm results with both PCA and ISOMAP clas-
sifiers. In figure 5.3 the PCA and ISOMAP results used features drawn from the sample by
sample affinity matrices. In figure 5.4 the PCA and ISOMAP results used features drawn
from the gene-by-gene affinity matrices. The a priori manifold learning algorithm was the
same in both figures.
The results for the Dunn index for sample-by-sample experiments in figure 5.3 and for
gene-by-gene experiments in figure 5.4 show that a priori manifold learning creates denser
clusters in all cases except colon, uterine and lung cancer. From the graph induced for
the colon dataset for both sample-by-sample and gene-by-gene experiments and the uter-
ine dataset in the gene-by-gene experiments it can be seen that a priori manifold learning
outperforms PCA and Isomap for embeddings with lower dimensions. The goal is to create
an embedding with as few components possible to represent the original high-dimensional
data. For the lung dataset in the sample-by-sample experiments more samples are needed
to create a more accurate embedding.
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Figure 5.3: Dunn Index for cancer classification results: The Dunn Index found using a
priori manifold learning (Blue) compared with PCA (Green) and Isomap (Red). PCA and
ISOMAP were computed using features from the sample-by-sample affinity matrix.
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Figure 5.4: Dunn Index for cancer classification results: The Dunn Index found using a
priori manifold learning (Blue) compared with PCA (Green) and Isomap (Red). PCA and
ISOMAP were computed using features from the gene-by-gene affinity matrix
5.4.2 Ten Fold Cross-Validation
To evaluate the accuracy of the embeddings k-NN and LDA classifiers were used with ten
fold cross-validation. In order to get the values, the trapezoidal rule which approximates the
definite integral of the plots was used. Results are shown in table 5.2 for sample-by-sample
experiments and in table 5.3 for gene-by-gene experiments using k-NN. The corresponding
results for LDA are shown in table 5.4 for sample-by-sample and in table 5.5 for gene-by-
gene experiments. The cases in which a priori manifold learning outperforms the rest of the
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methods are emphasised in bold. It should be noted that the variance is small enough such
that the individual accuracies of the experiments can be compared safely. The tables for
the variance can be found in Appendix B.1. In the LDA results a priori manifold learning
outperforms PCA and Isomap for 5 out of 9 datasets. These are the same datasets for both
sample-by-sample and gene-by-gene experiments. For k-NN, the results for the gene-by-
gene experiments show that a priori manifold learning outperforms the other two methods
in all cases, while for the sample-by-sample experiments, a priori manifold learning does
not perform so well.
When performing cross validation experiments both PCA and Isomap features can be com-
puted using either the gene-by-gene affinity matrix or the sample-by-sample affinity matrix.
The latter is a square matrix with dimension equal to the number of microarrays used in the
experiment. Each entry represents the similarity (or distance) between the corresponding
pair of microarrays. It is considerably smaller than the gene-by-gene matrix and conse-
quently more robust to noise. A priori manifold learning can only be computed using the
gene-by-gene affinity matrix. This is because the prior knowledge extracted from the KEGG
database is in the form of similarities between gene pairs. The results show that both PCA
and Isomap perform better using the sample-by-sample affinity matrix.
The sample-by-sample affinity matrix cannot be computed directly using a priori manifold
learning since it needs the genes for constructing the affinity matrix, and therefore a priori
manifold learning only operates on a gene-by-gene affinity matrix. For the GEMLeR dataset,
the sample-by-sample affinity matrix has dimensions 1545 by 1545. This is the number of
microarrays in the dataset. The gene-by-gene affinity matrix is 10935 by 10935 which is the
number of gene probes in each microarray.
The error bars with one standard deviation of uncertainty for the 10-fold cross validation
for the k-NN and the LDA classifier can be found in appendix B.2.
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Type Of Cancer A Priori Manifold Learning Isomap PCA
Breast cancer 0.806 0.863 0.879
Colon cancer 0.868 0.897 0.906
Kidney cancer 0.937 0.931 0.932
Ovary cancer 0.841 0.842 0.851
Lung cancer 0.902 0.911 0.917
Uterus cancer 0.891 0.890 0.891
Omentum cancer 0.914 0.912 0.912
Prostate cancer 0.955 0.954 0.954
Endometrium cancer 0.923 0.924 0.926
Table 5.2: Cancer classification accuracy measured using the k-Nearest Neighbours algo-
rithm and Ten Fold Cross validation: The results for PCA and ICA were computed using
features from sample-by-sample affinity matrices. The a priori manifold learning method
is either comparable with, or outperforms the others. The cases in which a priori manifold
learning outperforms the other methods are shown in bold.
Type Of Cancer A priorimanifold learning Isomap PCA
Breast cancer 0.806 0.782 0.792
Colon cancer 0.868 0.834 0.834
Kidney cancer 0.937 0.900 0.903
Ovary cancer 0.841 0.834 0.838
Lung cancer 0.902 0.883 0.886
Uterus cancer 0.891 0.882 0.881
Omentum cancer 0.914 0.912 0.912
Prostate cancer 0.955 0.943 0.945
Endometrium cancer 0.923 0.922 0.922
Table 5.3: Cancer classification accuracy measured using the k-Nearest Neighbours algo-
rithm and Ten Fold Cross validation: The results for PCA and ICA were computed using
features from gene-by-gene affinitymatrices. The a priori manifold learningmethod is either
comparable with, or outperforms the others. The cases in which a priori manifold learning
outperforms the other methods are shown in bold.
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Type Of Cancer A priorimanifold learning Isomap PCA
Breast cancer 0.890 0.901 0.912
Colon cancer 0.906 0.914 0.925
Kidney cancer 0.956 0.952 0.953
Ovary cancer 0.871 0.867 0.870
Lung cancer 0.935 0.938 0.941
Uterus cancer 0.906 0.900 0.905
Omentum cancer 0.927 0.923 0.924
Prostate cancer 0.973 0.972 0.972
Endometrium cancer 0.937 0.934 0.930
Table 5.4: Cancer classification accuracy measured using linear discriminant analysis
and ten fold cross validation: The results for PCA and ICA were computed using features
from sample-by-sample affinity matrices. The a priori manifold learning method is either
comparable with, or outperforms the others. The cases in which a priori manifold learning
outperforms the other methods are shown in bold.
Type Of Cancer A priorimanifold learning Isomap PCA
Breast cancer 0.890 0.888 0.910
Colon cancer 0.906 0.914 0.924
Kidney cancer 0.956 0.911 0.954
Ovary cancer 0.871 0.945 0.870
Lung cancer 0.935 0.924 0.940
Uterus cancer 0.906 0.901 0.905
Omentum cancer 0.927 0.926 0.923
Prostate cancer 0.973 0.970 0.972
Endometrium cancer 0.937 0.932 0.930
Table 5.5: Cancer classification accuracy measured using Linear Discriminant Analysis
and Ten Fold Cross validation: The results for PCA and ICA were computed using fea-
tures from gene-by-gene affinity matrices. The a priori manifold learning manifold learning
method is either comparable with, or outperforms the others. The cases in which a priori
manifold learning outperforms the other methods are shown in bold.
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Receiver Operating Characteristic Curves
In addition Receiver Operating Characteristic (ROC) curves were constructed to illustrate
the ratio of true positive to false positive results. Three different classification methods were
used to illustrate the effectiveness of a priori manifold learning .
k - Nearest Neighbours (k-NN)
For the k-NN classifier the results obtained for the ROC curves agree with the 10-fold cross
validation results. A priori manifold learning performs better in all the gene-by-gene exper-
iments as shown in figure 5.5, while in the sample-by-sample ones only performs better in
one dataset as shown in figure 5.6
Support Vector Machines (SVMs)
Using SVMs a priori manifold learning performs better in 6 out of 9 datasets for the gene-
by-gene experiments (figure 5.7) while in the sample-by-sample experiments (figure 5.8) it
performs better in all datasets.
Linear Discriminant Analysis (LDA)
For the same purpose LDA was used. For the gene-by-gene experiments the results are
shown in figure 5.9 and for sample-by-sample experiments the result are shown in figure
5.10. A priori manifold learning performs better in 5 out of 9 datasets.
Comparing the ROC curves of the three different classifiers shows that the a priori manifold
learning gives consistent results for LDA and SVMs for both gene-by-gene and sample-by-
sample experiments. However, the k-NN classifier seems to perform very well for the gene-
by-gene experiments but not for the sample-by-sample ones. A possible explanation for
this is that discriminant methods like SVMs and LDA use a data model computed from the
whole dataset, and may therefore be more robust to noise and other artefacts. By contrast
the k-NN classifier relies on the local distribution of the data, and could therefore be less
effective particularly in small sample size problems.
The Acute Lymphoblastic Leukaemia (ALL) dataset for leukaemia was analysed to demon-
strate how the different cells were clustered. The ALL dataset is simple enough to visualise
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Figure 5.5: ROC curves for cancer classification using k-Nearest Neighbours: A priori
manifold learning (blue) compared with PCA (Green) and Isomap (Red). PCA and ISOMAP
were computed using the gene-by-gene affinity matrix.
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Figure 5.6: ROC curves for cancer classification using k-Nearest Neighbours: A priori
manifold learning (blue) compared with PCA (Green) and Isomap (Red). PCA and ISOMAP
were computed using the sample-by-sample affinity matrix.
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Figure 5.7: ROC curves for cancer classification using support vector machines: A priori
manifold learning (blue) compared with PCA (Green) and Isomap (Red). PCA and ISOMAP
were computed using the gene-by-gene affinity matrix.
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Figure 5.8: ROC curves for cancer classification using support vector machines: A priori
manifold learning (blue) compared with PCA (Green) and Isomap (Red). PCA and ISOMAP
were computed using the sample-by-sample affinity matrix.
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Figure 5.9: ROC curves for cancer classification using Linear Discriminant Analysis: A
priori manifold learning (blue) compared with PCA (Green) and Isomap (Red). PCA and
ISOMAP were computed using the gene-by-gene affinity matrix.
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Figure 5.10: ROC curves for cancer classification using linear discriminant analysis: A
priori manifold learning (blue) compared with PCA (Green) and Isomap (Red). PCA and
ISOMAP were computed using the sample-by-sample affinity matrix.
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and has been used before [BTGM04] to demonstrate the clustering of the different types of
cells in two dimensions. The embedding with the samples annotated with their true labels
is found in figure 5.11.
Figure 5.11: Leukaemia cell: Two dimensional manifold of the three different leukaemia
cells. Clusters of the different cell types are formed and are easily distinguished in the
lower dimensional space.
5.4.3 Pathway Robustness
The robustness and the effectiveness of using pathways was shown by removing pathways
using a uniform distribution with different probabilities. By removing a percentage of the
KEGG pathways in different runs of the algorithm it is shown how the number of pathways
affects the performance. The results are shown in appendix B.3. In most cases removing
pathways results in reducing the accuracy as shown in the ROC curves and the Dunn index
graphs.
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5.5 Discussion
Conventional manifold learning algorithms, such as Isomap, aim to project the microarray
data to a lower dimensional space in which functionally different clusters are better sepa-
rated. The lower dimensional space is a manifold (hypersurface) contained in the original
data space and found from the local distribution of the data. A large representative dataset
is used to compute the manifold. This method provides a way of improving the way Isomap
finds the k-nearest points and creates the neighbouring graph by utilising KEGG pathway
information. The KEGG data is a form of prior knowledge which is better curated and more
reliable than the microarray data. Once the manifold has been constructed the raw microar-
ray data is projected onto it and clustering and classification can take place. The method
was called a priori manifold learning and was compared with the original Isomap and the
PCA algorithm, since PCA is the most commonly used method for dimensionality reduc-
tion. By incorporating prior knowledge it is argued that it can assist in having less variable
and more biologically significant clusters. The clusters were checked against the DAVID
database [HSL09b, HSL09a] and the majority of genes in the clusters were related to the
cancer to be classified. Information taken from KEGG pathways is a way of decreasing the
noise in the microarray experiments. Results were produced using ten different datasets of
cancer data, where the goal was to distinguish between different types of cancers. Nine out
of the ten datasets are considered to be high dimensional (10935 features).
The results were similar across the different datasets. In the first set of results, it was shown,
using the Dunn index, that a priori manifold learning is able to create denser clusters with
objects that lie closer to the mean of the cluster with a small variance. A priori manifold
learning produces more compact, well-separated clusters when compared with PCA and
the original Isomap. In some cases a priori manifold learning performs better only for em-
beddings with a smaller number of components which is still useful since the embeddings
with a lower number of dimensions are considered to be better. There were also cases where
the samples and the KEGG signatures were not enough for a priori manifold learning to
perform better than PCA and Isomap.
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A priori manifold learning on average performs better in many cases when using the LDA
and SVM classifiers. It does not do so well in classification experiments where PCA and
Isomap are computed using the sample-by-sample affinity matrix using the k-NN classifier.
In this case there is no significant difference between the three formulations. A possible
reason for this is that both LDA and SVM classifiers create a model of the underlying classes,
but k-NN is a parametric method which depends on the local distribution of the data, and
consequently may be more susceptible to noise.
Overall it can be seen that a priori manifold learning produces better formed clusters than
either PCA or Isomap, and also performs better in classification experiments using either
SVM or LDA methods in most cases. One of the drawbacks of the method is that it has only
been formulated using the gene-by-gene affinity matrix, and this makes it more prone to
noise than methods that can be computed directly on a sample-by-sample affinity matrix.
Incorporating prior knowledge using KEGG pathways is not only limited to cancer data
but it can be applied to a number of diseases that have KEGG signatures. This, along with
the fact that the method does not require any other information, makes it easy to adapt
to any kind of biological problem. Other studies [CX04, KZ10, CCM+04] have used Gene
Ontology (GO) terms instead of KEGG pathways. KEGG pathways carry more information
when it comes to diseases rather than GO terms since GO terms mostly give information
about the function of a gene and the annotation of the different gene products. GO terms
can be structured as graphs that show relationships between the different GO terms which
are separated in three different categories: (i) biological processes, (ii) functions and (iii)
cellular components. None of these provides any information of the gene interactions. They
only provide information on the different gene product properties. An implementation of a
priori manifold learning using GO terms is discussed in the next chapter.
Chapter 6
A PrioriManifold Learning Using GO
Terms
6.1 Introduction
A priori manifold learning was also implemented using Gene Ontology (GO) terms. Gene
Ontology provides a common language to describe the various gene products and allows
comparisons between products of different species. It provides a mark-up language for i)
maintaining a controlled vocabulary of gene and gene product attributes; ii) annotating
genes and gene products; and iii) providing tools to access the data in the Gene Ontology
database and enable functional interpretation of experimental data.
The gene products are described in terms of their associated biological processes, cellular
components and molecular functions. Biological processes are essential for a living organ-
ism (metabolism), cellular components are substances of which cells are composed (mem-
branes, organelles, proteins) and molecular functions describe activities that occur at the
molecular level (catalytic and binding activities). A gene product and its GO terms are
shown in figure 6.1.
A table showing gene HAAO with its associated GO Terms is shown in table 6.1. The GO
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Gene product: Actin, alpha cardiac muscle 1
GO term: heart contraction ; GO:0060047 (biological process)
Evidence code: Inferred from Mutant Phenotype (IMP)
Reference: PMID 17611253
Assigned by: UniProtKB, June 6, 2008
Figure 6.1: Gene Product Association with GO Term.
AB C
is-a
part-of regulates
has-part
1
Figure 6.2: GO Terms Relationships: GO terms relationships can be: is-a (is a subtype of);
part-of; has-part; regulates (negatively, positively).
terms are structured as directed acyclic graphs, and each term has defined relationships
to one or more other terms in the same domain, and sometimes to other domains. The
relationships are shown in figure 6.2 and are described as:
• is-a: A is a subtype of node B; e.g. Mitotic cell cycle is-a cell cycle
• part-of: if B exists it is always a part of A; e.g. Replication fork is necessarily part-of a
chromosome
• has-part: B always has C as a part, if B exists, C will always exist; e.g. Nucleus neces-
sarily has-part chromosome
• regulates: A affects C; e.g. Regulation of mitotic spindle organization regulates mitotic
spindle organization
Gene Name / Product Biological Process Cellular Component Molecular Function
HAAO
3-hydroxyanthranilate 3,4-dioxygenase
tryptophan catabolic process (GO:0006569)
response to zinc ion (GO:0010043)
quinolinate biosynthetic process(GO:0019805)
cytosol (GO:0005829)
extracellular exosome (GO:0070062)
3-hydroxyanthranilate 3,4-dioxygenase activity (GO:0000334)
protein binding (GO:0005515)
ferrous iron binding (GO:0008198)
electron carrier activity (GO:0009055)
Table 6.1: Gene HAAOMapped to GO Terms
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6.2 GO Terms Similarity Measures
The a priori manifold learning was implemented using the Jaccard coefficient as a similarity
measure. For GO terms however, there are alternative similarity measures that have been
proposed to make the comparison of GO terms more accurate.
Gene Ontology (GO) is widely used as the basis for measuring the functional similarity of
genes. Different similarity measures are split in two categories: Information content-based
methods and Graph-based methods.
6.2.1 Information Content-Based Methods
Thesemethods depend on the frequencies of the GO terms being compared and the frequen-
cies of their closest common ancestor term in a specific corpus of GO annotations (biological
processes, cellular components, molecular functions).
Resnik [Res95], Jiang and Conrath[JC97], Lin [Lin98] and Schlicker [SDRL06] similarities
are based on information theory. The relative frequency of a GO term t is defined as the sum
of all the times t is found in the set of GO terms over the total number of terms. Since the
probability of a GO term appearing depends on all the concepts it includes, it means that
the closer it is to the root, the more frequent it is. As frequency increases the informativeness
decreases. Therefore:
IC = − log(p(t)) (6.1)
where IC is the Information Content and p(t) is the frequency of a GO term t as shown in
equation 6.2.
p(t) =
nt
N
(6.2)
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where nt is the number of occurrences of t and its children in the GO term corpus with
N elements. IC can take values between 0 to 1. 0 means closer to the root therefore it is
uninformative and 1 means it is on a distant leaf.
Resnik defined similarity as:
simResnik(ti , tj ) = IC(MICA) (6.3)
where MICA is their most informative common ancestor. Resnik’s measure does not con-
sider how distant the terms are from their common ancestor. To take that distance into
account, Lin’s, Schlicker’s and Jiang and Conrath’s measures relate the IC of the MICA to
the IC of the terms being compared.
Lin’s similarity measure is a normalised version of Resnik’s similarity that takes into con-
sideration the Information Content of both terms:
simLin(ti , tj ) =
2× simResnik
IC(ti) + IC(tj )
(6.4)
Jiang and Conrath’s method is a distance metric (semantic distance) between two GO terms.
simJiang (ti , tj ) =
1
IC(ti) + IC(tj )− 2× IC(MICA) + 1 (6.5)
The similarity measure derived from the distance metric is shown below:
simJiang (ti , tj ) = 1−min(1, IC(ti) + IC(tj )− 2× IC(MICA)) (6.6)
Lin and Jiang and Conrath measures are displaced from the graph, which means that these
measures are proportional to the IC differences between the terms and their MICA, indepen-
dently of the absolute IC of the ancestor. To overcome this limitation, Schlicker’s measure
was proposed, based on Lin’s similarity, which uses the probability of selecting the MICA,
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as a weighting factor to provide graph placement.
Schlicker’s (or Relevance) similarity measure is a combination of Lin’s and Resnik’s mea-
sures:
simRel(ti , tj ) =
2× IC(MICA)× (1− p(MICA))
IC(ti) + IC(tj )
(6.7)
6.2.2 Graph-Based Method
Graph-based methods use the topology of the directed acyclic graph (DAG) of the GO terms
in order to calculate the semantic similarity. The DAG of a GO term ti can be represented as
DAGti = (ti , Tti , Eti ) where Tti is the set of GO terms in DAGti including ti and its ancestors
and Eti are the edges in DAGti .
Wang [WABD04] similarity measure works by first defining the semantic value of term ti as
the combined contribution of all terms in DAGti with terms closer to ti contributing more
to its semantics. For any term in DAGti its contribution (S-value) is defined as Sti (tk) where
tk ∈DAGti is defined as:

Sti (ti) = 1
Sti (tk) =max(we × Sti (t′)|t′ ∈ children(tk)andtk , ti)
where we is the semantic factor of the edge e ∈ Eti between the term tk and its child t′.
we can be the type of GO relationship the two terms have (e.g is-a relationship or part-
of relationship) which means that we can have different weights based on the relationship
type. The sum of all terms in Sti in DAGti is defined as:
SVti =
∑
t∈Tti
Sti (t) (6.8)
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Therefore for two terms ti and tj the Wang similarity is calculated as:
Sti ,tj =
∑
t∈Tti∩Ttj (Sti (t) + Stj (t))
SVti + SVtj
(6.9)
where Sti (t) is the S-value of GO term t related to term ti and Stj (t) is the S-value of GO term
t related to term tj . Wang’s similarity, measures the semantic similarity of two GO terms
based on their locations on the GO graph and their relations with their ancestors.
6.3 Results Using The Jaccard Coefficient
Following the same procedure as before a priori manifold learning was applied on the same
cancer datasets. The Dunn index was used evaluating the density and the structure of the
clusters. K-Nearest Neighbours (k-NN), Support Vector Machines (SVMs) and Linear Dis-
criminant Analysis (LDA) classifiers were applied along with 10-fold cross validation to test
the accuracy of the model.
6.3.1 Internal Evaluation
Dunn Index
For the Dunn index the graphs compared to PCA and Isomap are shown in figures 6.3 for
the sample-by-sample transformation and for the gene-by-gene transformation in figure
6.4. The Dunn index of the clusters is higher than PCA and Isomap in four occasions for the
sample-by-sample transformations (Endometrial, Kidney, Prostate and Uterine) and seven
occasions for the gene-by-gene transformations (all but Breast and Colon).
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Figure 6.3: Dunn Index for cancer classification results: The Dunn Index found using
a priori manifold learning with GO terms (Blue) compared with PCA (Green) and Isomap
(Red). PCA and ISOMAP were computed using features from the sample-by-sample affinity
matrix.
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Figure 6.4: Dunn Index for cancer classification results: The Dunn Index found using
a priori manifold learning with GO terms (Blue) compared with PCA (Green) and Isomap
(Red). PCA and ISOMAP were computed using features from the gene-by-gene affinity
matrix
6.3.2 Ten Fold Cross-Validation
When applying cross-validation using k-NN, SVMs and LDA it was observed that themodels
for some of the cancers over-fit, since the cross-validation variance was too high. This is
shown in table 6.2 for k-NN, in table 6.5 for SVMs and in table 6.6 for LDA. The results
when compared with PCA and Isomap using k-NN are shown in table 6.3 and table 6.4 for
genes-by-gene and sample-by-sample transformations respectively. For LDA the results are
shown in table 6.7 for genes-by-gene and table 6.8 for sample-by-sample.
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Type Of Cancer A Priori Manifold Learning (GO) Variance
Breast cancer 0.892 0.0008
Colon cancer 0.937 0.0001
Kidney cancer 0.971 0.0001
Ovary cancer 0.873 2.501e-05
Lung cancer 0.924 3.419e-05
Uterus cancer 0.919 8.136e-06
Omentum cancer 0.950 7.466e-06
Prostate cancer 0.995 4.034e-05
Endometrium cancer 0.961 3.247e-06
Table 6.2: 10 Fold Cross Validation Accuracy using k-Nearest Neighbours: The results of
the 10-fold cross-validation on the dataset show that some of the models over-fit (shown in
bold).
Type Of Cancer A priorimanifold learning (GO) Isomap PCA A Priori Manifold Learning (KEGG)
Breast cancer 0.892 0.782 0.792 0.806
Colon cancer 0.937 0.834 0.834 0.868
Kidney cancer 0.971 0.900 0.903 0.937
Ovary cancer 0.873 0.834 0.838 0.841
Lung cancer 0.924 0.883 0.886 0.902
Uterus cancer 0.919 0.882 0.881 0.891
Omentum cancer 0.950 0.912 0.912 0.914
Prostate cancer 0.995 0.943 0.945 0.955
Endometrium cancer 0.961 0.922 0.922 0.923
Table 6.3: Cancer classification accuracy measured using the k-Nearest Neighbours algo-
rithm and Ten Fold Cross validation: The results for PCA and ICA were computed using
features from gene-by-gene affinity matrices. The a priori manifold learning algorithm using
GO terms outperforms the other methods in most cases (shown in bold).
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Type Of Cancer A Priori Manifold Learning (GO) Isomap PCA A Priori Manifold Learning (KEGG)
Breast cancer 0.892 0.863 0.879 0.806
Colon cancer 0.937 0.897 0.906 0.868
Kidney cancer 0.971 0.931 0.932 0.937
Ovary cancer 0.873 0.842 0.851 0.841
Lung cancer 0.924 0.911 0.917 0.902
Uterus cancer 0.919 0.890 0.891 0.891
Omentum cancer 0.950 0.912 0.912 0.914
Prostate cancer 0.995 0.954 0.954 0.955
Endometrium cancer 0.961 0.924 0.926 0.923
Table 6.4: Cancer classification accuracy measured using the k-Nearest Neighbours algo-
rithm and Ten Fold Cross validation: The results for PCA and ICA were computed using
features from sample-by-sample affinity matrices. The a priori manifold learning algorithm
using GO terms outperforms the other methods in most cases (shown in bold).
Type Of Cancer A Priori Manifold Learning (GO) Variance
Breast cancer 0.908 9.034e-05
Colon cancer 0.867 0.001
Kidney cancer 0.964 0.0001
Ovary cancer 0.836 0.002
Lung cancer 0.926 0.0003
Uterus cancer 0.746 0.049
Omentum cancer 0.896 0.001
Prostate cancer 0.988 4.106e-05
Endometrium cancer 0.905 0.001
Table 6.5: 10 Fold Cross Validation Accuracy using Support Vector Machines: The results
of the 10-fold cross-validation on the dataset show that some of the models over-fit (shown
in bold).
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Type Of Cancer A Priori Manifold Learning (GO) Variance
Breast cancer 0.955 5.709e-05
Colon cancer 0.963 7.840e-05
Kidney cancer 0.982 2.566e-05
Ovary cancer 0.885 1.005e-05
Lung cancer 0.967 7.038e-05
Uterus cancer 0.913 0.0001
Omentum cancer 0.930 7.164e-05
Prostate cancer 0.997 8.379e-07
Endometrium cancer 0.916 0.0004
Table 6.6: 10 Fold Cross Validation Accuracy using Linear Discriminant Analysis: The
results of the 10-fold cross-validation on the dataset show that some of the models over-fit
(shown in bold).
Type Of Cancer A priorimanifold learning (GO) Isomap PCA A Priori Manifold Learning (KEGG)
Breast cancer 0.955 0.888 0.910 0.890
Colon cancer 0.963 0.914 0.924 0.906
Kidney cancer 0.982 0.911 0.954 0.956
Ovary cancer 0.885 0.945 0.870 0.871
Lung cancer 0.967 0.924 0.940 0.935
Uterus cancer 0.913 0.901 0.905 0.906
Omentum cancer 0.930 0.926 0.923 0.927
Prostate cancer 0.997 0.970 0.972 0.973
Endometrium cancer 0.916 0.932 0.930 0.937
Table 6.7: Cancer classification accuracy measured using Linear Discriminant Analysis
and ten fold cross validation: The results for PCA and ICA were computed using features
from gene-by-gene affinity matrices. A priori manifold learning using GO terms outper-
forms the other methods in most cases (shown in bold).
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Type Of Cancer A priorimanifold learning (GO) Isomap PCA A Priori Manifold Learning (KEGG)
Breast cancer 0.955 0.901 0.912 0.890
Colon cancer 0.963 0.914 0.925 0.906
Kidney cancer 0.982 0.952 0.953 0.956
Ovary cancer 0.885 0.867 0.870 0.871
Lung cancer 0.967 0.938 0.941 0.935
Uterus cancer 0.913 0.900 0.905 0.906
Omentum cancer 0.930 0.923 0.924 0.927
Prostate cancer 0.997 0.972 0.972 0.973
Endometrium cancer 0.916 0.934 0.930 0.937
Table 6.8: Cancer classification accuracy measured using Linear Discriminant Analysis
and ten fold cross validation: The results for PCA and ICA were computed using features
from sample-by-sample affinity matrices. A priori manifold learning using GO terms out-
performs the other methods in most cases (shown in bold).
Receiver Operating Characteristic Curves
The ROC curves are shown in the appendix C, even though the models are not considered
reliable since they over-fit. A lot of models seem to over-fit for all the classifiers used. This
makes the cross-validation accuracy and the ROC curves (true positives and false negatives)
inconsistent since the variance was very high. The accuracy for the models that do not
over-fit was higher than all the scores obtained for PCA and Isomap by both gene-by-gene
and sample-by-sample transformations. Only one cancer model does not over-fit by any
classifier and that is Prostate cancer.
Over-fitting
It is clear from the information obtained from the cross-validation that the test error is
much higher than training error for most of the datasets. This is a way of knowing that
the models do over-fit and they cannot be trusted as an accurate representation of the data
[GS03]. Since the algorithm is using the entire dataset it is expected that the variance of
the dataset should be similar to the variance of the model which is not the case here. The
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high variance observed shows the fluctuation in the predictions of the different folds during
cross-validation.
6.4 Results Using Wang Similarity
The Jaccard coefficient can be replaced with the Wang or the Lin similarity for GO terms
which can make the similarity score a lot more accurate. Unfortunately, the running time
for the datasets was far too high, and it was impossible to get any results in a reasonable
time.
When calculating the distance matrices and the GO term similarities there were more than
100 million comparisons to be made due to the size of the dataset (10935 × 10935). Every
gene can be associated with a number of GO terms and bothWang and Lin work by pairwise
comparisons of those genes. That means that the number of comparisons per gene (k) com-
bination is gComb = k×k (worst case). These algorithms work by finding the ancestors of the
two terms and calculating the information content which is O(n2) (average case) in terms of
computational complexity. The complexity is super-linear and it grows as the size of the
problem grows (if the size doubles, the time for solving the problem more than doubles).
The total average complexity is ≈O(gComb ×n2).
In addition the Wang similarity creates a DAG which it then traverses in order to find the
ancestors and the children of each ancestor. It constructs the DAG, finds the common ances-
tors between two genes and calculates the semantic contribution for all ancestors. If genes
A and B have k ancestors in common then the worse case complexity will be 2× k ×n2 since
for genes A and B two different DAGs are constructed and the computation for each takes
place separately. This is again done in pairwise combinations ≈O(gComb × k ×n2)
It takes about 1 minute per comparison to get the similarity score for each pair of GO terms
when using Wang. It will take approximately 83000 days to finish the calculation. The Lin
similarity measure is slightly faster than the Wang similarity; it takes about 45 seconds per
comparison which will take about 62000 days to finish.
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Even when only one GO term per gene is selected at random, the algorithms are still too
slow - using Lin similarity will take approximately 208 days to finish while Wang will need
1383.
6.4.1 Comparison With A PrioriManifold Learning Using Pathways
The models created with a priori manifold learning do not show any signs of over-fitting.
That makes the pathway results more reliable than the GO terms results. In addition, for
two of the models created using GO terms the η value was zero or near zero which means
that the GO information was not taken into account significantly or not at all. This shows
that for Prostate and Uterine cancer the models generated were just like the original Isomap
algorithm; with the only difference being that instead of Euclidean distance, Mahalanobis
distance is used. This explains the improvement in accuracy seen in some of the cases. The
Dunn index for the pathways is much higher than the GO terms’ for all cancers, which
implies that the quality of the clusters is better when using pathways as a source of prior
knowledge.
6.5 Discussion
In this chapter a modification to a priori manifold learning was presented in order to eval-
uate the use of GO terms as prior knowledge. Two different ways were shown for the cal-
culation of the similarity measure for each pair of GO terms. The first one uses Jaccard
coefficient as before and the other uses the Wang and Lin GO term similarity measures. The
second way however was infeasible due to computational limitations even though it would
be a more accurate measure of GO terms similarity. Using the Jaccard coefficient the results
obtained were not reliable since the models for the different cancers over-fit. All cancers
(except Prostate) over-fit (as shown by the variance of the models using LDA, SVMs and
k-NNs) and therefore the results were not accurate. This is due to the abstract nature of
GO terms, which are used as a way of describing gene products rather than providing infor-
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mation on relationships between genes, which pathway data provide. A gene is associated
with a lot more GO terms than pathways. GO terms have 3 different categories: biological
processes, cellular components and molecular functions; and different types of relation-
ships: is-a, part-of, has-part, and regulates; which is information about the annotation of
the different gene products; while pathway information describes interactions among those
genes. The same annotation i.e.tryptophan catabolic process; does not imply any sort of in-
teraction, even though a number of genes can end up having the same annotation. For this
reason, it seems that even genes that are not strongly related tend to have very high Jaccard
coefficients which leads to a wrong distance matrix. Getting a higher coefficient for genes
with the same annotation could mean that the model captures the noise instead of the actual
information of the dataset.
When constructing the a priori manifold learning embeddings it was apparent that the best
model for prostate cancer was the one where the GO terms were not taken into account at
all and therefore the η value was 0. For uterine cancer the model’s η value was only 800
which means that the GO terms were taken into account only slightly. The difference in
the accuracy between an η of 800 and an η value of 0 for uterine cancer is only 0.01. In
addition when using different models, created by a priori manifold learning using GO terms
(with a different η value), it was observed that the variance could be much lower but the
accuracy was also very low (≈0.7) for all the cancers. There was no good balance between
variance and accuracy. This is known as the bias–variance trade-off. For the models where
the variance was low the η value was near 0 for all cases.
Chapter 7
Identifying Significant Features In Cancer
Methylation Data Using Gene Pathway
Segmentation
7.1 Introduction
The latest worldwide cancer statistics, provided by GLOBOCAN 2012, have shown that ap-
proximately 14.1 million people suffered from cancer in 2012. The number is expected to
rise to 24 million in 20 years time1. Some advances have been made in the identification of
genes related to the cancer aetiology. All these have led to the expansion of our understand-
ing of the genetic mechanisms that are driving cancer progression.
Recent improvements in molecular biology technology have allowed the measurement and
profiling of DNA methylation sites in large genomic samples [SKK+06]. DNA methylation
is believed to be closely related to gene expression [ASH13, Boc12] and DNA methylation
sites have been increasingly found to be related to the processes of cancer [Lau08, LM12].
Methylation biomarkers have also been associated with the response of a patient to par-
ticular treatment of cancer as shown in some clinical studies [MDH+05, Bay05]. Machine
1http://www.cancerreasearchuk.org
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learning has been widely used on biological data with increasing success [WTH+05, OS10,
LSC+09]. Methylation data however has only recently been analysed usingmachine learning
[RJG+12].
Due to the high dimensionality of the methylation datasets, direct use of many machine
learning methods is computationally intractable, and it is necessary to find a method of
selecting significant features to analyse. Current methylation data may have in excess of
450,000 probes (n), and perhaps 100 patient cases (D). The computational complexity of
PCA – the simplest and most fundamental method in multivariate data analysis is at least
n× n×D, which can make the analysis infeasible. To overcome this, a new feature selection
approach is proposed in which methylation data is combined with prior knowledge taken
from biological pathways. Prior knowledge has been used before for the classification of
microarray expression [BGL+00, GHHZ09, HTG14, CX04, KZ10, CCM+04, CW09b]. Little
has been done in terms of predicting response to cancer treatment using methylation data
and prior knowledge. For this experiment pathway information from the ConsensusPath
database [KSLH13, KPG+11, KWLH09, POH+10] was used. The dataset was split into path-
way sets and then each pathway set was analysed individually in order to see which sets
can provide accurate classification. The ConsensusPath database integrates different types
of information including: protein interactions, genetic interactions signalling, metabolism,
gene regulation and drug target interactions in humans. These are taken from a number
of databases including Reactome, KEGG, HumanCyc, PID and BioCarta. AdaBoost with
decision trees as weak classifiers was applied on the sets inferred from the ConsensusPath
database in order to classify response to treatment. Boosting techniques can help with re-
ducing the bias in supervised learning by being less susceptible to the over-fitting problem
than other learning algorithms [Kea98].
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7.2 Feature SelectionOver Pathway SegmentationAlgorithm
In order to reduce the computation time and improve the accuracy each dataset was split
into a number of subsets using information in the ConsensusPath database [KSLH13, KPG+11,
KWLH09, POH+10]. Genes that belong in the same pathway were put in the same gene set.
As a result the datasets were divided into 3213 smaller sets mostly between 100 and 2000
genes each. A gene can belong to more than one pathway. The method is shown in figure
7.1 and works as follows:
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Figure 1: As a first step the original methylation dataset, is split into smaller
sets based on pathway information we got from the ConsensusPath database.
AdaBoost is applied on the smaller sets and using stratified cross-validation
(to account for unbalanced classes) the accuracy score of each pathway was
calculated. A number of random sets was created so that the pathway sets with
the highest score could be verified using z-score and p-values.
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Figure 7.1: Pathway Algorithm: As a first step the original methylation dataset, is split
into smaller sets based on pathway information taken from the ConsensusPath database.
AdaBoost is applied on the smaller sets using stratified cross-validation (to account for un-
balanced classes), and the accuracy score of each pathway is calcul ted. A number of ran-
dom sets are created so that the pathway s ts with the highest score could be verified using
z-score and p-values.
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• Split the dataset into subsets defined by pathways;
• Apply AdaBoost for classifying the response to treatment in each subset;
• Find the subsets that can predict progression accurately using z-scores and p-values;
• Recombine the successful pathway sets using the accuracy of the tree and the Gini
importance of its features to construct a set of features that can accurately classify the
dataset.
The relation between the different probe locations relative to each gene (island, shore, shelf)
is not taken into account, instead the focus was on gene pathway sets that can influence
response. For the probes to gene mapping two different methods were attempted:
1. Normalising the probes that belong to the same gene by dividing their methylation
values by their mean and picking the probe with the highest intensity;
2. Using all the probes in the classifier.
Both methods identified the same sets of genes since probes that match the same gene are
correlated [SH07] and decision trees use correlated features interchangeably. If the tree
becomes repetitive it gets pruned [TL11] so leaving all the probes in can be much faster.
7.3 Datasets
For our feature selection over pathway segmentation algorithm two methylation dataset
(Chronic myeloid leukaemia (CML) and TCGA Lower Grade Glioma (LGG)) were used.
In the CML methylation dataset there were 429 231 probes with 91 samples, 60 of them
were responsive to blood cancer treatment while 31 were not and in the LGG (http://
cancergenome.nih.gov/) there were 370 203 probes with 82 samples, 57 of them were not
responsive to treatment (Progressive Disease) while 25were (Complete Remission/Response).
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Information on the contents of the datasets is shown in table 7.1.
Type Of Cancer Number Of Samples Number Of Genes
Chronic Myeloid Leukaemia 60 responsive vs 31 non-responsive 429231
TCGA Lower Grade Glioma 25 responsive vs 57 non-responsive 370203
Table 7.1: Datasets Used
Lower Grade Glioma
Primary brain tumours emerge from various cells that make up the brain and central ner-
vous system and are named after the cell they originate from. Approximately 42% patients
survive for one year. This rate however drops to 14% ≈ 16% after five years and 9% after ten
years. There are many types of brain cancer (meningioma, medulloblastoma, gliomas) and
different types of gliomas: Astrocytomas (originating from astrocyte cells) which include:
low-grade astrocytomas, anaplastic astrocytoma and glioblastoma multiforme; oligoden-
drogliomas (originating from oligodendrocytes); ependymoma (originating from ependy-
mal cells) [BG14].
Chronic Myeloid Leukaemia
Leukaemia is the 11th most common cancer for both sexes and it accounts for 2.5% of all
cancers with ≈ 352 000 new cases worldwide every year2. The exact cause of leukaemia is
not yet known but it is believed that is related to both environmental and inherited factors.
This type of cancer originates in the bone marrow and results in a high number of leukaemia
cells (abnormal white blood cells which are not fully developed) [Nat13]. Approximately
63% ≈ 64% patients survive for one year. This rate however drops to 44% after five years
and 32% ≈ 33% after ten years. There are four major types of leukaemia:
1. Acute Lymphoblastic Leukaemia (ALL): Starts in abnormal lymphoid stem cells and
progresses very quickly [Wei14].
2http://www.cancerresearchuk.org/
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2. Acute Myelogenous Leukaemia (AML): Starts in abnormal myeloid stem cells and de-
velops quickly [Sei14].
3. Chronic Lymphocytic Leukaemia (CLL): Starts in abnormal lymphoid stem cells and
take months or even years to develop [Cle79].
4. Chronic Myelogenous Leukaemia (CML): Starts in abnormal myeloid stem cells and
develops slowly [Bes14].
AML, CLL and CML are mainly adult cancers. They are very rarely encountered in children.
ALL however is a cancer that is very common in children. Acute leukaemia usually develops
quickly and worsens in some weeks unless treated, in contrast to chronic forms of leukaemia
that progress very slowly and can be left untreated for months or years. Even though a lot of
progress has been made over the years for the treatment of CML leukaemia, 30% to 35% of
patients do not respond to treatment [CBD+13]. A drug called Imatinib, a tyrosine-kinase
inhibitor, is the first line of treatment for CML and was introduced in 1988 [COJT+97, SS11].
The Chronic Myelogenous Leukaemia Methylation Dataset is unpublished.
7.4 Experiments Using The Pathway Algorithm
7.4.1 Baseline Experiments
Initially the complete datasets for LGG and CMLwere analysed using principal components
analysis (PCA) [Pea01] for linear dimensionality reduction and manifold Isomap [TdSL00]
for non-linear feature extraction. Sample-by-sample affinity matrices were used since gene-
by-gene matrices were very large and even after several hours of computation did not yield
any result. The results obtained were not significant in terms of accuracy and are shown in
table 7.2. The ROC curves are as shown in figure 7.2 for LGG (left) and CML (right).
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Figure 7.2: ROC Curve for the original LGG (left) and CML (right) datasets: Dimension-
ality reduction was performed using both PCA and Isomap, and classification was made
using AdaBoost.
Dataset Accuracy Variance
CML with PCA 0.6044 0.0222
CML with Isomap 0.5155 0.0159
LGG with PCA 0.7083 0.0177
LGG with Isomap 0.6347 0.0289
Table 7.2: Accuracy of the original datasets: Results for the original datasets using lin-
ear (PCA) and non-linear (Isomap) forms of dimensionality reduction and AdaBoost. The
results are not significant in terms of accuracy.
7.4.2 TCGA Lower Grade Glioma
Pathways
Classification for LGG treatment response was performed on all pathway sets with a num-
ber of genes greater than 100. Four gene pathway sets had accuracy between 0.88 ∼ 0.90.
To estimate the accuracy 10 fold stratified cross-validation was used, as shown in table 7.3.
The p-values show that the random null hypothesis can be rejected and therefore the re-
sults are significant in the 99% confidence interval. The Receiver operating characteristic
(ROC) curves were plotted for the identified gene pathway sets (figure 7.3). Dimensionality
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reduction on those gene pathway sets worsens the results as shown in figure 7.4. The ROC
curves for two other gene pathway sets that do not perform so well were compared to the
Pantothenate and CoA biosynthesis set (figure 7.5). The accuracy for the gene pathway sets
when logistic regression is applied instead of AdaBoost is shown in table 7.4. The results are
not significant in terms of accuracy. The AdaBoost method performs better since the deci-
sion trees split the dataset several times instead of just once and because boosting methods
tend to remove bias from the results by re-sampling.
Pathway Name Accuracy Variance Z-Score P-Value
Pantothenate and CoA biosynthesis - Homo sapiens (human) 0.904 0.0191 3.9713 0.000036
Transcription factor creb and its extracellular signals 0.891 0.0163 3.68249905 0.000116
Pyrimidine metabolism 0.890 0.0070 3.65034371 0.000131
IL2 0.879 0.0056 3.39268741 0.000346
Table 7.3: Gene pathway sets with the highest scores for LGG: Gene pathway sets for LGG
and their accuracies and variances after 10 fold Stratified Cross-Validation
Figure 7.3: ROC curves for the LGG Pathway Sets: ROC curves for the four gene pathway
sets with the highest accuracy
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Figure 7.4: Pantothenate and CoA biosynthesis and Retinoate Biosynthesis II pathway
set: Comparison of the pathway set, with and without dimensionality reduction (PCA and
Isomap)
Figure 7.5: Comparison between Pantothenate and CoA biosynthesis and Retinoate
Biosynthesis II (left) and Activation of Rac (right) pathway sets
Pathway Name Logistic Regression
Pantothenate and CoA biosynthesis - Homo sapiens (human) 0.708
Transcription factor creb and its extracellular signals 0.697
Pyrimidine metabolism 0.650
IL2 0.674
Table 7.4: Logistic Regression applied on LGG: Results for logistic regression on LGG gene
pathway sets
Each gene was removed from the four gene pathway sets to see the effect it had on the
accuracy. It is shown that some genes have more effect than others and removing them
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affects the accuracy negatively. This is shown figures 7.6, 7.7, 7.8. In addition random gene
sets were created to verify the effectiveness of the pathways. The class distribution was the
same in all random sets since the samples were left intact. The number of genes was different
in every set, but the sets generated followed the distribution of the number of genes in the
pathway sets. The graphs for the highest-scoring gene pathway sets against random gene
sets were constructed. These results are shown in figure 7.9. 980 random sets were used to
check the significance of the result. The z-score was used to calculate the difference from
the mean of the accuracy for the random sets and also the highest scoring gene pathway sets.
The p-values were calculated using the z-score obtained. Comparing the accuracy of all the
random sets, after 10 different runs it was observed that the accuracies vary between 0.4 and
0.71. Their variance is either equal or much greater than the variance of the pathway sets.
The variance of the random sets is between 0.018 and 0.0287. This shows that the genes
belonging to the pathway sets used in this method can play an important role in classifying
cancer.
Figure 7.6: 50% of the genes were removed from the IL2 (left) and Pantothenate and CoA
biosynthesis (right) pathway sets
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Figure 7.7: 20% of the genes were removed from the IL2 (left) and the Pantothenate and
CoA biosynthesis (right) pathway sets
Figure 7.8: 50% of the genes were removed from the IL2 pathway set
Figure 7.9: Comparison between IL2 and a random gene pathway set of 1170 genes (left)
and between Pyrimidinemetabolism and a random gene pathway set of 644 genes (right)
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Gene Set
A more comprehensive set of genes with discriminative properties was then composed by
combining several successful pathway sets that were identified by the algorithm shown in
algorithm 7.1. To obtain this set AdaBoost was applied on all gene pathway sets. The gene
pathway sets with the highest accuracy were selected. Looking closely at how AdaBoost
builds the decision classifiers the features (genes) that were important when building the
decision tree were identified and the ones that were not as important were filtered out. An
important feature for a decision tree is one for which the weights are higher. It indicates
how well the nodes of the decision tree are partitioned by that feature. The importance of
a feature is related to its height in the tree with the root being the most important. This is
also known as the Gini importance.
Several classifiers with different combinations of threshold values were constructed and the
combination with the highest accuracy score was chosen. The algorithm is shown in algo-
rithm 7.1. AccuracyThreshold had values between 0.7− 0.9 and GiniImportanceThreshold
had different values ranging from 0.003 to 0.5. Table 7.5 shows the resulting set of genes
which can classify progression with an accuracy of 99%. Genes that have been previously
associated with gliomas appear in bold. The p-value of this set is 0.00140625 showing that
it is significant in the 99% confidence interval.
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Algorithm 7.1. Gene Selection Algorithm based on accuracy thresholds and how impor-
tant each feature is when constructing the decision tree3
Data: Methylation Data
for p ∈ PathwaySet do
if accuracy(p) > AccuracyThreshold then
for feature ∈ DecisionTree(p) do
if importance(feature) > GiniImportanceThreshold then
GeneSet← feature
end if
end for
end if
end for
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Gene Name Functional Annotation
DDOST Dolichyl-Diphosphooligosaccharide–Protein Glycosyltransferase Subunit
PRKAR2B protein kinase, cAMP-dependent
PDPK1 3-phosphoinositide dependent protein kinase 1
PIK3CD phosphatidylinositol-4,5-bisphosphate 3-kinase
CDC16 cell division cycle 16
OAT ornithine aminotransferase
KRAS Kirsten Rat Sarcoma Viral Oncogene Homolog
NTRK1 neurotrophic tyrosine kinase, receptor, type 1
NF1 neurofibromin 1
BTRC beta-transducin repeat containing E3 ubiquitin protein ligase
PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (gamma)
KCNMB4 potassium large conductance calcium-activated channel, subfamily M, beta member 4
IFNGR1 interferon gamma receptor 1
SC5DL sterol-C5-desaturase
ATF2 activating transcription factor 2
GABRB2 gamma-aminobutyric acid (GABA) A receptor, beta 2
STX1A syntaxin 1A (brain)
GPX4 glutathione peroxidase 4
GAB2 GRB2-associated binding protein 2
EIF2AK1 eukaryotic translation initiation factor 2-alpha kinase 1
SOS1 son of sevenless homolog 1 (Drosophila)
EXOC6 exocyst complex component 6
IRS1 insulin receptor substrate 1
ANK1 ankyrin 1, erythrocytic 2
IL6R interleukin 6 receptor
NRCAM neuronal cell adhesion molecule
SLC22A2 solute carrier family 22 (organic cation transporter), member 2
PPCDC phosphopantothenoylcysteine decarboxylase
UPB1 ureidopropionase, beta
PTK2B protein tyrosine kinase 2 beta
ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)
STAT3 signal transducer and activator of transcription 3 (acute-phase response factor)
SLCO4A1 solute carrier organic anion transporter family, member 4A1
SLCO2A1 solute carrier organic anion transporter family, member 2A1
Table 7.5: Gene List for LGG: Combined Gene List of the most influential genes for LGG
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7.4.3 Chronic Myeloid Leukaemia
Pathways
The gene pathway sets with the highest scores for the CML data set are shown in table 7.6
The p-values show that the result is significant in the 99% confidence interval. Classification
was performed on all gene pathway sets in order to see how well each of them could classify
CML progression. Two gene pathway sets were isolated that had an accuracy of 0.9888.
The accuracy of the Regulation of the KIT signalling pathway set was also calculated using
two different methods of dimensionality reduction. Dimensionality reduction once again
worsens the results as shown figure 7.11.
Pathway Name Accuracy Variance Z-Score P-Value
Regulation of KIT signaling 0.9888 0.0011 6.44028444 <0.00001
Signaling events mediated by Stem cell factor receptor (c-Kit) 0.9888 0.0011 6.44028444 <0.00001
Superpathway of D-myo-inositol(1,4,5)-trisphosphate metabolism 0.8244 0.0176 2.11346295 0.0176
Table 7.6: Gene pathway sets with the highest scores for CML: Gene pathway sets for
CML and their accuracies and variances after 10 Fold Stratified Cross-Validation
Figure 7.10: ROC curves for the CML Pathway Sets: ROC curves for the CML Pathway Sets
for the two gene pathway sets with the highest accuracy
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Figure 7.11: Regulation of KIT signalling pathway set: Comparison of the pathway set,
with and without dimensionality reduction (PCA and Isomap)
The Receiver Operating Characteristic (ROC) curves for the two gene pathway sets with the
highest accuracies were plotted (figure 7.10). The ROC curves for two other gene pathway
sets that do not perform so well compared with the Regulation of KIT signalling set are
shown (figures 7.12 and 7.13). The results for logistic regression are shown in table 7.7.
Genes were again removed from the gene pathway sets to see the effect it had on the accu-
racy. Again some genes have more effect than others and removing them affects the accuracy
negatively. This is shown in figures 7.14 and 7.15.
Figure 7.12: Comparison between Regulation of KIT signalling and Arrestins in gpcr de-
sensitization (left) and NF-kappa B signalling pathway - Homo sapiens (right) pathway
sets
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Figure 7.13: Comparison between Regulation of KIT signalling and Acetylcholine Syn-
thesis
Pathway Name Logistic Regression
Regulation of KIT signaling 0.703
Signaling events mediated by Stem cell factor receptor (c-Kit) 0.693
Superpathway of D-myo-inositol(1,4,5)-trisphosphate metabolism 0.682
Table 7.7: Logistic Regression applied on CML: Results for logistic regression on CML gene
pathway sets
Figure 7.14: 60% of the genes were removed from the Regulation of KIT signalling path-
way
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Figure 7.15: 80% of the genes were removed from the Regulation of KIT signalling path-
way
Comparing the accuracy of all the random sets (shown in figures 7.16, 7.17), after 10 dif-
ferent runs it is observed that the accuracies vary between 0.4 and 0.7. Their variance is
either equal to or much greater than the variance of the pathway sets. The variance of the
two gene pathway sets is 0.0011 while for the random sets variance is between 0.0165 and
0.0260. The random gene pathway sets were used to calculate the z-score of the accuracy
and the p-values of the random sets compared to the two highest scoring gene pathway sets.
Figure 7.16: Comparison between Regulation of KIT signalling and a random pathway
set of 644 genes (left) and a random pathway set of 1170 genes (right)
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Figure 7.17: Comparison between Regulation of KIT signalling and a random pathway
set of 728 genes
Gene SH2B3
Even though the purpose of this study was not to identify single genes, a single gene seemed
to stand out. By studying how the AdaBoost was constructing the classifier models for the
data, it was apparent that the CpG island cg00056489, which translates to gene SH2B3
or SH2B adaptor protein 3, was the gene that most of the modelling was based on. In fact
removing this gene only from the pathway set reduced the classification accuracy to random
(≈ 0.5) from the initial 0.99 before removal.
Gene Set
Another set of genes that is important to classification was constructed. The accuracy of
this set was 0.94. The list of genes is shown in table 7.8 with the genes previously associated
with CML shown in bold. SH2B3 was deliberately excluded from the list so it will not bias
the result.
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Gene Name Functional Annotation
INPP5A polyphosphate-5-phosphatase, 40kDa
INPP5B inositol polyphosphate-5-phosphatase, 75kDa
IMPAD1 inositol monophosphatase domain containing protein 1
INPP1 inositol polyphosphate-1-phosphatase
INPP5J inositol polyphosphate-5-phosphatase J
ITPKB inositol 1,4,5-trisphosphate 3-kinase B
SYNJ2 synaptojanin 2
Table 7.8: Gene List for CML: Combined Gene List of the most influential genes for CML
7.5 Discussion
In this chapter a novel way of analysing big datasets by segmenting them based on prior
pathway information is presented. Analysing the genes belonging to a pathway separately
can give some information as to how a disease is related to that pathway and which biolog-
ical mechanisms are involved. It also reduces the number of the variables to be analysed
significantly, since now we are dealing with small pathway sets instead of the whole methy-
lation dataset, and makes the computation tractable as shown in table 7.9. There were four
pathway sets for LGG and two for CML and two lists of genes that show statistical associa-
tion with response to treatment. Further experimentation, analysis and clinical significance
testing must be performed to determine whether these results can be used to define an ef-
fective biomarker in a clinical setting in the battle against LGG and CML.
Pathway Size Computational Time
≈ 100 ≈ 3 seconds
≈ 500 ≈ 7 seconds
≈ 1000 ≈ 14 seconds
≈ 1000 ≈ 17 seconds
≈ 2000 ≈ 21 seconds
Table 7.9: Computational Complexity Using Pathway Segmentation
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Four pathway sets were found that can classify progression and response to treatment accu-
rately for LGG. All of them have previously been associated with gliomas and brain cancer.
Pantothenate and CoA biosynthesis is related to brain neurodegeneration and iron accumu-
lation in the brain [MC11]. Studies have shown that the ratio between iron and zinc affects
the malignancy of the tumour [WCW+13]. IL2 (Interleukin 2) was first used in the treatment
of glioma in 1986 as part of immunotherapy treatments [OKZ+09]. Moreover Pyrimidine
metabolism in human gliomas is increased by comparison to normal brain [VBL94]. The
last pathway is related to the transcription factor creb. Transcription factor creb is shown
to be over-expressed in gliomas [TWZ+12] and it is related to their proliferation [DFB+14].
In addition a pathway set that had an accuracy of 0.85 is worth noting. This is the Renal
cell carcinoma pathway. It was shown that Renal cell carcinoma (RCC) is one of the most
common sources of brain metastases [RLM12]. From the optimal set of genes that was found
response can be predicted very accurately (0.99). Some of the genes in the set have already
been associated with gliomas. In particular, signal transducer and activator of transcription
3 has been associated with inducing the progression and formation of gliomas [KPR+14] ;
Gab2 is related to glioma tumour invasion [SSZ+13]; NTRK1 has been associated with the
different grades of glioma [PAV14] and KRas can initiate the growth of gliomas [HW05].
For CML, Gene SH2B3was shown to be statistically related to the response to CML leukaemia
treatment. SH2B adapter protein 3 is a protein that in humans is encoded by the SH2B3 gene
[MMRK96, HTMZ+97]. Its role is to be involved in a range of signalling activities by growth
factor and cytokine receptors. It is a member of the family of tyrosine kinase adapter pro-
teins [ASK+99], the high-affinity cell surface receptors for many polypeptide growth factors,
cytokines, and hormones [RWL00], which are shown to be involved with the progression of
many types of cancer. The possibility of manipulating receptor tyrosine kinase signalling
in order to prevent cancer or enhance cancer therapy was explored previously [ZBU01]. It
is a key protein for the negative regulator of cytokine signalling and plays a critical role in
hematopoiesis. This kind of cell is very much related with leukaemia [Sac96, Nat13]. More
over SH2B3 has already been identified as a predisposition gene to Acute Lymphoblastic
Leukaemia (ALL) [Wil13].
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From the set of genes that can also predict response very accurately (0.94), inositol polyphosphate-
5-phosphatase has already been associated with leukaemia in [MJN+94]. In addition it is
associated with SH2 since it encodes a protein in that domain. The protein is related to
hematopoietic cells and its movement from the cytosol to the plasma membrane is medi-
ated by tyrosine phosphorylation [LSJ+98]. Synaptojanin was also found in the set which
belongs to the inositol-polyphosphate 5-phosphatase family that has previously been asso-
ciated with hairy cell leukaemia, a chronic mature B-cell leukaemia characterized by malig-
nant B cells that have typical hairy protrusions [SDVDVDM+03].
7.6 A prioriManifold Learning Over Pathway Segmentation
A priori manifold learning was applied on the pathway sets extracted from both the CML
and the LGG datasets. The algorithm over-fits, as expected, since the datasets are already
split into pathway sets and a priori manifold learning increases the importance of the fea-
tures that exist in the same pathway. Given that they are already separated into pathway
sets then all the features are classified as equally important. The accuracies were between
0.85 and 1 for all pathway sets. The results are obviously not reliable since the classifier
needs to be trained on more general data.
Chapter 8
Conclusion
The aim of this thesis is to introduce some new methods for dimensionality reduction of
cancer datasets using prior knowledge. The contribution is the development and testing of
two novel dimensionality reduction algorithms, one of which is a feature extraction method
and the other one is a feature selection method. Data from various biological databases that
contain information about gene pathways were combined with already existing dimension-
ality reduction algorithms. In addition a number of machine learning methods were used
for linear and non-linear dimensionality reduction and classification and were compared
with the proposed methods. Both algorithms can work with other forms of microarray data
and are not limited to cancer. In this chapter, the accomplishments presented in this thesis
are summarised with some suggestions for future work. Part of the future work has already
been undertaken as a master’s project with my guidance.
8.1 Thesis Summary
Chapter 1: describes the motivation for this thesis and the contributions. It briefly intro-
duces the a priori manifold learning and the feature selection over pathway segmentation
algorithms.
Chapter 2: introduces the microarray technology, explains how microarrays are used and
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what are the different types. It includes an explanation of how the analysis of microarray
data works.
Chapter 3: gives a mathematical background of the dimensionality reduction and classifica-
tion methods used throughout this thesis. Methods include: Principal Components Analy-
sis, manifold - Isomap, Support Vector Machines, Linear Discriminant Analysis, k - Nearest
Neighbours, AdaBoost with decision trees as weak classifiers, internal cluster validation and
Cross Validation.
Chapter 4: provides a background on the current progress in machine learning applied on
microarray data and introduces the main problems, which are the curse of dimensionality
and the noise that can be found in this kind of data. It also explains the two ways of per-
forming dimensionality reduction, feature selection and feature extraction, how they are
different and how they have been used up to now.
Chapter 5: explains the a priori manifold learning algorithm and the way prior knowl-
edge was used in constructing the manifold instead of filtering out data. A priori manifold
learning was compared in terms of cluster density and accuracy using three different classi-
fication methods with principal components analysis and the conventional Isomap. A priori
manifold learning performs significantly better than the other methods.
Chapter 6: implements a modification of the a priori manifold learning algorithm described
in chapter 5 which incorporates information from the GO terms database. The results are
not as good as with pathways since most of the models created over-fit and that makes the
accuracy and the cluster quality unreliable. For the few models that do not over-fit the ac-
curacy is higher than the accuracy obtained by a priori manifold learning using pathway
information.
Chapter 7: describes the feature selection over pathway segmentation algorithm. The effec-
tiveness was proven using a CML leukaemia and a Lower Grade Glioma dataset for which
pathways were identified, and in the case of CML leukaemia a single gene that seems to
be statistically related to the response to treatment. In addition lists of genes are shown,
that can be equally effective in predicting response. The classification method used was
AdaBoost using decision trees as weak classifiers. The results from this chapter can be used
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to undertake further clinical research in order to investigate further the involvement of the
genes in question to CML and LGG.
Chapter 8: concludes the thesis with a summary of the contributions and future work.
To conclude, in chapters 5, 6 and 7 two novel methods of feature extraction and feature
selection for biological datasets that incorporate prior knowledge from on-line pathway
databases are described. Biological datasets can be exceptionally noisy and are high-dimensional
and therefore prior knowledge can help improving the accuracy and overcome noise. A key
point was that prior knowledge was combined with the Isomap algorithm in such a way so
that it can only be used when constructing the manifold and not for filtering data out as
is the case with most methods that make use of prior knowledge. The method was much
more effective without increasing the complexity of the algorithm. In addition the CML
dataset that was deemed impossible to analyse up to now due to its very high dimension-
ality was successfully analysed. It was broken down in pathways and each pathway was
analysed separately. A gene was discovered, that has been associated with other forms of
leukaemia before, that is related to the response to CML treatment. The gene was included
in the two higher scoring pathways found to be related to CML. Four pathways were found
to be related to LGG and lists of genes that can classify response to treatment with very high
accuracy for CML and LLG were composed.
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8.2 Future Work
8.2.1 A PrioriManifold Learning Using Locally-Linear Embedding
Locally-linear embedding (LLE) [RS00] appeared around the same time as Isomap and has
several advantages over Isomap which include faster optimization and sparse matrix algo-
rithms. A comparison between the two is shown in table 8.1.
Isomap Locally Linear Embedding
Applies Multidimensional Scaling
(MDS) on the geodesic distances
Models local neighbourhoods as linear re-
lations and then embeds them on a lower
dimension
Global approach that preserves the
mapping and geometry of all points
which gives a more faithful represen-
tation
Local approach that might not be as accu-
rate but it is faster (polynomial speed-up)
due to sparse matrix computations. Could
find results whose local geometry is close
to Euclidean but not their global geometry
Might fail for non–convex manifolds Can work with any manifold
Table 8.1: Comparison between Isomap and Locally Linear Embedding
8.2.2 Learning Causality Using Bayesian Networks
An extension to the feature selection over pathway segmentation algorithm was proposed
in a master’s thesis [Suk15] by Nimalesh Sukumar. In his thesis Sukumar investigated ways
in which the causality between the genes in the dataset could be inferred.
Constrained Based Bayesian Learner
The gene pathway sets were analysed using a constrained based Bayesian learner. The first
step of the algorithm was to infer the Bayesian Network with undirected edges and then
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use different hypotheses to construct the directed edges. The null hypothesis in this case
is that the genes are independent. The X2 statistic shown in equation 8.1 was used with
a 95% confidence interval to test the hypothesis. Continuous and discrete learners were
used. Continuous Learners assume linear relationships between genes, while for discrete
learners the data had to be quantised using different number of quantiles. The continuous
learner performed the worst (no edges were identified), while the discrete learner with 2
quantiles performed better. The performance was measured using the number of Bayesian
networks produced with the highest number of edges (41 of the pathways had 6 or more
edges). However only quantising the dataset in 2 quantiles leads to loss of information and
therefore the results were not accurate.
X2 =
∑
i
(Oi −Ei)
Ei
(8.1)
Kruskal’s AlgorithmWith Mutual Information
A different method using Kruskal’s algorithm applied to mutual information was used. For
this experiment only a subset of the pathways was used which only included the 4 high-
est scoring pathways from the Lower Grade Glioma dataset. The algorithm is shown in
algorithm 8.1. The equation used as the dependency metric is the mutual entropy or the
Kullback-Leibler divergence shown in equation 8.2. Boosting was also applied to test the
robustness of the algorithm. The dataset was sampled with replacement 100 times to pro-
duce sets with the same number of data points as the original dataset as shown in algorithm
8.2.
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Algorithm 8.1. Kruskal’s algorithm
for each pair of genes in dataset do
calculate mutual entropy
order variable pairs in terms of mutual entropy
A is empty set
for each gene G in dataset do
Make-Set (G)
for each (a,b) in ordered mutual entropy list do
if GET-SET(a) does not equal GET-SET(b) then
A = A union (a,b)
end if
end for
end for
end for
Algorithm 8.2. Boosting algorithm
for j = 1 to 100 do
GenSet is empty set
while i ≤ N do
let k be random int in 1 to N
add sample k to GenSet
increment i
end while
Apply Bayesian Network Algorithm to GenSet
end for
CondDep(A,B) =
∑
AXB
P(ai&bj )log2
P(ai&bj )
P(ai)P(bj )
(8.2)
The results showed that when the labels of the samples were not taken into account, many
edges kept appearing a large number of times during the boosting process. The mutual in-
formation with the 95% confidence interval show that 8 edges satisfy the constraint. Specif-
ically gene ANK1 had a significant dependency with SLC04A1, PIK3CD, GPX4, STAT3
and IRS1. When the labels were taken into account for the responsive to treatment pa-
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tients, there were no significant results while for the unresponsive patients the edge ANK1–
PIK3CD appeared to be significant
Marginal Independence
An experiment to identify colliders (shown in figure 8.1) was also conducted using marginal
independence. The marginal independence algorithm (shown in algorithm 8.3) was run on
the Bayesian networks identified using the Kruskal’s algorithm. A score function using both
the conditional independence and the mutual entropy was used to score the colliders as
shown in equation 8.3.
A
C
B
1
Figure 8.1: A Collider
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Algorithm 8.3. Marginal Independence
for VarA in GeneSet do
for VarCent in GeneSet do
for VarB in GeneSet do
if VarA-VarCent AND VarCent-VarB in Bayesian Network then
calculate CondDep on (VarA,VarB,VarCent)
calculate Mutual Information on (VarA,VarB)
add (VarA,VarB,VarCent) to Collider List
end if
end for
end for
end for
CondDep =
CondInt(A,B,C)−MutEntr(A,B)
CondInt(A,B,C)
(8.3)
When the algorithmwas run on the Bayesian networks without the labels taken into account
one collider was identified (NF1, STX1A, NRCAM) with a high score. When the labels for
the unresponsive and responsive Patients were taken into account the algorithm identified
12 colliders for unresponsive patients and 11 for the responsive ones. GAB2 was consis-
tently the child variable in 5 out of the 11 colliders identified in the responsive patients.
Cyclic Bayesian Networks
In order to identify potential cycles in the dataset and have directed edges in the networks
the Cyclic Bayesian algorithm was used (shown in algorithm 8.4). The dataset for this ex-
periment only included the 4 highest scoring pathways. It identified 4,729 colliders which
made the identification of any important relations impossible. A threshold on the number
of edges allowed in the network was added (2 × number of vertices, which would be ap-
proximately double the edges in a connected tree), and it produced 12 edges that were the
same as the ones identified by the Kruskal algorithm. The marginal independence algo-
rithm was run in order to identify colliders but nothing significant was produced. Inferring
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the causality on the dataset unfortunately did not yield significant results.
Algorithm 8.4. Cyclic Bayesian Networks
for each pair of genes in dataset do
calculate mutual entropy
end for
order variable pairs in terms of mutual entropy
V isitedV ertices is emptyset
BayesNet is emptyset
for each (v1, v2) in ordered mutual entropy list do
if v1 not in V isitedV ertices then
Add v1 to V isitedV ertices
if v2 not in V isitedV ertices then
Add v2 to V isitedV ertices
add (v1, v2) to BayesNet
if len(V isitedNodes) ≥ threshold then
Break
end if
end if
end if
end for
Overall Bayesian methods for identifying to identify conditional relationships and interac-
tions among genes did not yield any meaningful result. Improvements to the above meth-
ods could be made in order to incorporate prior knowledge from directed gene pathway
databases. A combination of the prior knowledge and the information found in the mi-
croarray dataset might be shown to be a better of way of identifying relationships among
genes.
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170 Appendix A. Cell Cycle
Phase Description
Interphase G0 Resting Phase: The cell performs normal functions
Interphase G1 Gap 1 - first growth phase: The cell prepares to start division
Interphase S Synthesis phase: The cell copies its DNA
Interphase G2 Gap 2 - second growth phase: The cell makes more proteins be-
fore it divides
Prophase
Metaphase
Anaphase
Telophase
M Mitosis: The cell divides into 2 new cells
Table A.1: The stages of the cell cycle 1
1http://www.cancer.ca/en/cancer-information/cancer-101/what-is-cancer/the-cell-cycle/
?region=on
Appendix B
A prioriManifold Learning
B.1 Variances
The variances for the k-NN classifier for the gene-by-gene experiments are shown in table
B.1 and for the sample-by-sample experiments in table B.2. For the LDA the variance is
shown in table B.3 for the gene-by-gene experiments and in table B.4 for the sample-by-
sample experiments. The variance was calculated using 10 fold cross-validation.
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Type Of Cancer A Priori Manifold Learning Isomap PCA
Breast cancer 32.09034e-5 37.52164e-5 35.38524e-5
Colon cancer 29.24537e-5 29.91476e-5 28.95183e-5
Kidney cancer 6.72999e-5 11.64989e-5 12.68591e-5
Ovary cancer 21.39207e-5 11.13463e-5 12.88114e-5
Lung cancer 14.09877e-5 5.26385e-5 3.13050e-5
Uterus cancer 13.01978e-5 3.44257e-5 5.51030e-5
Omentum cancer 2.54772e-5 0.80620e-5 0.80620e-5
Prostate cancer 2.34272e-5 6.79816e-5 4.34986e-5
Endometrium cancer 1.58922e-5 1.92059e-5 1.10440e-5
Table B.1: 10 Fold Cross Validation Variance On a Gene-by-Gene Transformation using
k-Nearest Neighbours: The results show that the variance of the cross validation is very
small and thus we can safely compare the methods tested.
Type Of Cancer A Priori Manifold Learning Isomap PCA
Breast cancer 32.09034e-5 27.91171e-5 18.32800e-5
Colon cancer 29.24537e-5 26.86585e-5 16.95718e-5
Kidney cancer 6.72999e-5 10.34294e-5 9.40982e-5
Ovary cancer 21.39207e-5 24.88867e-5 14.85025e-5
Lung cancer 14.09877e-5 14.62143e-5 12.39355e-5
Uterus cancer 13.01978e-5 16.97889e-5 18.60610e-5
Omentum cancer 2.54772e-5 2.79939e-5 2.12314e-5
Prostate cancer 2.34272e-5 2.07739e-5 2.17724e-5
Endometrium cancer 1.58922e-5 5.77868e-5 6.19262e-5
Table B.2: 10 Fold Cross Validation Variance On a Sample-by-Sample Transformation
using k-Nearest Neighbours: The results show that the variance of the cross validation is
very small and thus we can safely compare the methods tested.
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Type Of Cancer A Priori Manifold Learning Isomap PCA
Breast cancer 4.43639e-5 3.18558e-5 1.64494e-5
Colon cancer 3.97728e-5 1.79713e-5 5.60684e-5
Kidney cancer 6.28824e-5 2.24769e-5 2.73758e-5
Ovary cancer 2.94021e-5 3.21893e-5 3.50449e-5
Lung cancer 1.58082e-5 2.14339e-5 1.26192e-5
Uterus cancer 1.04442e-5 7.45783e-5 7.01667e-5
Omentum cancer 1.21062e-5 3.76439e-5 2.42125e-5
Prostate cancer 4.12092e-5 1.40641e-5 4.41161e-5
Endometrium cancer 1.14222e-5 1.62528e-5 8.67444e-5
Table B.3: 10 Fold Cross Validation Variance On a Gene-by-Gene Transformation using
Linear Discriminant Analysis: The results show that the variance of the cross validation is
very small and thus we can safely compare the methods tested.
Type Of Cancer A Priori Manifold Learning Isomap PCA
Breast cancer 4.43639e-05 2.70937e-5 1.62271e-5
Colon cancer 3.97728e-5 3.55322e-5 5.32299e-5
Kidney cancer 6.28824e-5 4.56036e-5 3.06760e-5
Ovary cancer 2.94021e-5 2.80513e-5 4.17136e-5
Lung cancer 1.58082e-5 1.97068e-5 1.47822e-5
Uterus cancer 1.04442e-5 4.53130e-05 7.25349e-5
Omentum cancer 1.21062e-5 9.24128e-5 2.14339e-5
Prostate cancer 4.12092e-5 1.25679e-5 2.42809e-5
Endometrium cancer 1.14222e-5 8.63512e-5 8.75652e-5
Table B.4: 10 Fold Cross Validation Variance On a Sample-by-Sample Transformation
using Linear Discriminant Analysis: The results show that the variance of the cross vali-
dation is very small and thus we can safely compare the methods tested.
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B.2 Accuracy error
For the k-NN gene-by-gene experiments the graphs are shown in figure B.1 and for the
sample-by-sample in figure B.2. For the Linear Discriminant Analysis gene-by-gene exper-
iments graphs are shown in figure B.3 and for the sample-by-sample in figure B.4. The
accuracy was calculated using 10 fold cross-validation.
Figure B.1: Accuracy with variance for all nine datasets using the gene-by-gene affinity
matrices k-Nearest Neighbours: Accuracy with variance calculated for a priori manifold
learning (blue) compared with PCA (Green) and Isomap (Red) computed using the gene-
by-gene affinity matrix and the k-NN classifier
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Figure B.2: Accuracy with variance for all nine datasets using the sample-by-sample
affinity matrices using k-Nearest Neighbours: Accuracy with variance calculated for a pri-
ori manifold learning (blue) compared with PCA (Green) and Isomap (Red) computed using
the sample-by-sample affinity matrix and the k-NN classifier
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Figure B.3: Accuracy with variance for all nine datasets using the gene-by-gene affinity
matrices using Linear Discriminant Analysis: Accuracy with variance calculated for a pri-
ori manifold learning (blue) compared with PCA (Green) and Isomap (Red) computed using
the gene-by-gene affinity matrix and the LDA classifier
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Figure B.4: Accuracy with variance for all nine datasets using the sample-by-sample
affinity matrices using Linear Discriminant Analysis: Accuracy with variance calculated
for a priori manifold learning (blue) compared with PCA (Green) and Isomap (Red) com-
puted using the sample-by-sample affinity matrix and the LDA classifier
B.3 Pathway Robustness
We show how the Dunn Index is affected in the Endometrium (figure B.5), Prostate (figure
B.6) and Lung (figure B.7) datasets. We also show how the ROC curves are affected for Breast
in figure B.8, Colon in figure B.9, Kidney in figure B.10, Omentum in figure B.11 and Ovary
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in figure B.12.
Figure B.5: Pathway Robustness (Endometrium): A plot of the Dunn Index with different
percentages of pathways
Figure B.6: Pathway Robustness (Prostate): A plot of the Dunn Index with different per-
centages of pathways
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Figure B.7: Pathway Robustness (Lung): A plot of the Dunn Index with different percent-
ages of pathways
Figure B.8: Pathway Robustness (Breast): A plot of ROC curves with different percentages
of pathways
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Figure B.9: Pathway Robustness (Colon): A plot of ROC curves with different percentages
of pathways
Figure B.10: Pathway Robustness (Kidney): A plot of ROC curves with different percent-
ages of pathways
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Figure B.11: Pathway Robustness (Omentum): A plot of ROC curves with different per-
centages of pathways
Figure B.12: Pathway Robustness (Ovary): A plot of ROC curves with different percentages
of pathways
Appendix C
A prioriManifold Learning using GO
terms
C.1 ROC Curves
The ROC curves for the k-NN classifier for the gene-by-gene experiments are shown in fig-
ure C.1 and for the sample-by-sample experiments in figure C.2. For the LDA they are
shown in figure C.3 for the gene-by-gene experiments and in figure C.4 for the sample-by-
sample experiments. For the SVMs the gene-by-gene experiments can be found in figure
C.5 for the sample-by-sample experiments in figure C.6. In all cases the a priori manifold
learning method uses features from the gene-by-gene affinity matrix to build the manifold.
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Figure C.1: ROC curves for gene-by-gene affinity matrices using k-Nearest Neighbours:
ROC curves found for a priori manifold learning (blue) compared with PCA (Green) and
Isomap (Red) computed using the gene-by-gene affinity matrix and the k-NN classifier.
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Figure C.2: ROC curves for sample-by-sample affinity matrices using k-Nearest Neigh-
bours: ROC curves found for a priori manifold learning (blue) compared with PCA (Green)
and Isomap (Red) computed using the sample-by-sample affinity matrix and the k-NN clas-
sifier.
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Figure C.3: ROC curves for gene-by-gene affinity matrices using Linear Discriminant
Analysis: ROC curves found for a priori manifold learning (blue) compared with PCA
(Green) and Isomap (Red) computed using the gene-by-gene affinity matrix and Linear Dis-
criminant Analysis.
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Figure C.4: ROC curves for sample-by-sample affinity matrices using Linear Discrimi-
nant Analysis: ROC curves found for a priori manifold learning (blue) compared with PCA
(Green) and Isomap (Red) computed using the sample-by-sample affinity matrix and Linear
Discriminant Analysis.
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Figure C.5: ROC curves for gene-by-gene affinity matrices using Support Vector Ma-
chines: ROC curves found for a priori manifold learning (blue) compared with PCA (Green)
and Isomap (Red) computed using the gene-by-gene affinity matrix and Support Vector Ma-
chines.
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Figure C.6: ROC curves for sample-by-sample affinitymatrices using Support VectorMa-
chines: ROC curves found for a priori manifold learning (blue) compared with PCA (Green)
and Isomap (Red) computed using the sample-by-sample affinity matrix and Support Vector
Machines.
Appendix D
Acronyms
ALL: Acute Lymphoblastic Leukaemia
ANOVA: Analysis Of Variance
BDLDA : Block Diagonal Linear Discriminant Analysis
BIRS: Best Incremental Ranked Subset
BPFS: Biological Pathway - based Feature Selection Algorithm
CART: Classification And Regression Tree
cDNA : Complementary DNA
CFS: Correlation - Based Feature Selection
CML : Chronic Myeloid Leukaemia
DNA: Deoxyribonucleic Acid
EWUSC: Error - Weighted Uncorrelated Shrunken Centroid
GA: Genetic Algorithms
GA-SVM: Genetic Algorithm - Support Vector Machine
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190 Appendix D. Acronyms
GLGS: Gradient - based - Leave - One - Out Gene Selection
GO: Gene Ontology
IC: Information Content
k-NN: k - Nearest Neighbours
KEGG: Kyoto Encyclopedia of Genes and Genomes
LDA: Linear Discriminant Analysis
LLE: Locally - Linear Embedding
LOOCSFS: Leave - One - Out Calculation Sequential Forward Selection
LOOCV: Leave - One - Out Cross Validation
LOOE: Leave - One - Out Cross - Validation Error
LOWESS: Locally Weighted Scatter Plot Smoothing
MAQC: MicroArray Quality Control
MBD: Methyl - Binding Domain
MDS: Multi - Dimensional Scaling
mRNA: Messenger Ribonucleic Acid
PCA: Principal Components Analysis
PPI: Protein - To - Protein Interaction
R-SVM: Recursive - Support Vector Machine
RNA: Ribonucleic Acid
ROC: Receiver Operating Characteristic
SAMBA: Statistical - Algorithmic Method for Bicluster Analysis
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SC: Shrunken Centroid
SFC: Sequential Forward Selection
SFS: Sequential Forward Selection
SNP: Single - Nucleotide Polymorphism
SOMs: Self Organizing Maps
SPCA: Supervised Principal Components Analysis
SVM: Support Vector Machine
SVM - RFE: Support Vector Machines - Recursive Feature Elimination
TCGA LGG: The Cancer Genome Atlas Lower Grade Glioma
USC: Uncorrelated Shrunken Centroid
